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Abstract
The collection of microbes and their genomic activity within us, referred to as the human
microbiome, is crucial in maintaining health, and disruptions in composition and/or
activity have been associated with various diseases. Considering the importance of breast
milk in neonatal development and the high rate of breast cancer in women, the objective
of my thesis was to obtain a comprehensive analysis of the microbiota of the mammary
glands and to examine the influence of these organisms on health and disease.
Human milk is an important source of bacteria for the developing infant. While a variety
of studies over the last 20 years have provided a greater appreciation for how diverse and
variable the milk microbiota is, little is known about these bacterial communities. Many
studies have emphasized the adverse effects of antibiotics on the infant microbiota,
however the impact of drugs on the lactating mother has not been studied. In Chapter 2
we report the changes caused by chemotherapy (over a 4 month period) on the milk
microbiota and metabolome of a woman undergoing treatment for Hodgkin’s lymphoma.
In Chapter 3, we show from a study of 39 Canadian women that neither gestation, mode
of delivery nor gender of the child explains the diversity of the milk microbiota.
As milk is not sterile and given the nutrient-rich fatty composition of the breast and its
exposure to the external environment via the nipple, we hypothesized that breast tissue
has its own indigenous microbiota. In Chapter 4, we confirmed this in a study of breast
tissue from 81 Canadian and Irish women, with the discovery of diverse bacterial
communities dominated by the phylum Proteobacteria. To determine whether this tissue
microbiota could play a role in breast cancer development, we compared, in Chapter 5,
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bacterial profiles in tissue between women with breast cancer and those who were
disease free. We show that differences do exist and that women with cancer have higher
numbers of bacteria with the ability to induce host DNA damage.
This work forms the platform for further studies that examine how breast milk and tissue
are first colonized and how these microbiotas can be manipulated to promote optimal
maternal and infant health.

Keywords
Human microbiome, breast milk microbiome, breast tissue microbiome, 16S rRNA gene
sequencing, breast cancer, DNA damage
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Chapter 1

1

General introduction

1.1 Functional anatomy of the female breast
The mammary gland, as the “mammary” part implies, is an organ unique to mammals,
with the main purpose of delivering nutrients and protective immunity to the baby in the
form of milk. But before milk can be produced and secreted, a complex and coordinated
process of gland morphogenesis occurs during three stages of human development;
embryogenesis, puberty and reproduction.

1.1.1

Embryogenesis

Human mammary gland morphogenesis starts with the formation of the milk line (lateral
thickening of the ectoderm) which then gives rise to a single pair of placodes (Robinson,
2007). These placodes later transform into bulbs of epithelial cells, which invaginate into
the underlying mesenchyme becoming “mammary buds” (Gjorevski and Nelson, 2011).
During the later stages of embryogenesis, the mammary buds start to proliferate and
elongate, forming sprouts that push down and out of the mesenchyme and into the
stromal fat pad, located within the dermis (Hens and Wysolmerski, 2005). These sprouts
concomitantly develop a lumen with an opening to the skin via the nipple (Macias and
Hinck, 2012). Once the sprouts have reached the fat pad, ductal branching occurs,
regulated by the stromal environment (Pavlovich et al., 2010; Tan et al., 2014; Wiesen et
al., 1999). This branched network gives rise to what is known as the “rudimentary ductal
tree” consisting of a primary duct and 15-20 secondary branches (Hens and Wysolmerski,
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2005). This structure is what is present at birth and will remain as such until puberty
(Figure 1-1, top).

1.1.2

Puberty

The pubertal stage is characterized by ductal elongation accompanied by secondary
branching. Unlike the embryonic stage, which is independent of hormone regulation, this
stage is initiated by elevated levels of estrogen (Silberstein et al., 1994), working in
concert with estrogen receptor (Feng et al., 2007) and growth hormone (Gallego et al.,
2001). At the tips of these elongating and branching ducts is a structure termed the
terminal end bud (TEB), which is a highly proliferative cap that “drives” the elongating
duct into the fat pad (Hinck and Silberstein, 2005). After successive rounds of elongation
and branching, when the limits of the fat pad have been reached, growth ceases and TEBs
disappear (Humphreys et al., 1996) (Figure 1-1, bottom)

1.1.3

Reproduction

While the hallmark of the pubertal stage is elongation and secondary branching, the
hallmark of the reproductive stage (pregnancy/lactation) is formation of extensive tertiary
branches (i.e. side branches) and the differentiation of TEBs into alveoli which produce
milk during lactogenesis (Robinson et al., 1995) (Figure 1-1, bottom). This process is
dependent on progesterone, progesterone receptor and prolactin (Atwood et al., 2000;
Gallego et al., 2001; Lydon et al., 1995). During lactogenesis, the breast is composed of
mostly glandular tissue with very few adipocytes (Ramsay et al., 2005). While the
mammary gland has the ability to synthesize milk throughout pregnancy, this does not
occur due to the high levels of progesterone secreted by the placenta, which acts as a
negative regulator of milk production (Djiane and Durand, 1977; López-Fontana et al.,
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2012). Once progesterone levels have decreased at parturition, copious amounts of milk
are produced at approximately 2 days post partum.
Cessation of lactation is followed by a phase known as involution, characterized by
apoptosis of milk producing epithelial cells, clearance of these apoptotic cells and milk
components and repopulation of the stroma with adipocytes (Alexander et al., 2001;
Clarkson et al., 2004; Lund et al., 1996; O’Brien et al., 2012; Walker et al., 1989). It is
estimated that about 80% of milk producing cells will undergo regulated apoptosis in
only a few days (Watson and Khaled, 2008). To prevent inflammation associated with
cellular debris, involution must be efficient and rapid. While clearance of apoptotic
bodies is usually associated with professional phagocytes such as macrophages, it has
been shown that mammary epithelial cells, rather than macrophages, are involved in
removing cellular debris and milk fat globules during post-lactational involution (Monks
et al., 2005, 2008).
Although the mammary gland reverts back to its pre-pregnancy state after involution, the
ductal network retains a more extensive framework of side branching than nulliparous
glands (Fendrick et al., 1998).
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Figure 1-1. Stages of mammary gland development
Top panel, embryonic; Bottom panel, post embryonic
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1.1.4

Structure of ducts and alveoli

The ducts and alveoli are composed of a bi-layered epithelium consisting of (i) an inner
layer of luminal epithelial cells that surround a hollow lumen, which differentiate into
milk producing alveoli during pregnancy/lactation and (ii) an outer layer of myoepithelial
cells, that upon oxytocin-mediated contraction triggers the release of milk through the
ducts (Gjorevski and Nelson, 2011). In 2006, Shackleton and colleagues isolated
mammary stem cells from adult mice and demonstrated that a single stem cell could give
rise to these luminal and myoepithelial cells and could generate a complete functional
gland when transplanted into gland-free mammary fat pads of C3H mice (Shackleton et
al., 2006).
This bi-layered epithelium is surrounded by an extracellular basement membrane
embedded within the stroma (a.k.a. fat pad) which consists of adipocytes, fibroblasts,
blood vessels and immune cells which all play a crucial role in optimal mammary
development (Gjorevski and Nelson, 2011). For example, macrophages, eosinophils and
mast cells are recruited from the connective tissue and lymph nodes in the stroma to the
TEB in the pubertal mammary gland to promote ductal elongation and branching
(Gouon-Evans et al., 2000; Lilla and Werb, 2010). These leukocytes are essential, as in
their absence, ductal growth is abrogated and the glands retain a neonatal appearance
(Gouon-Evans et al., 2000).

1.2 Human microbiome
The term “human microbiome”, was coined in 2001 by Joshua Lederberg who defined it
as the “ecological community of commensal, symbiotic and pathogenic microorganisms
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that literally share our body space” (Lederberg, 2001). These microorganisms consist of
viruses, fungi, archaea and eukaryotes, with bacteria making up the majority of
organisms present (99%) (Qin et al., 2010). While the terms “human microbiome” and
“human microbiota” are often used interchangeably, the latter refers to the microbial taxa
associated with humans, while the former refers to the collection of microbial taxa and
their genes (Ursell et al., 2012).
The human microbiota consists of trillions of microbial cells. The gastrointestinal tract
(GIT) alone harbours 100 trillion microbes, 1000 different species, 7000 bacterial strains
and 3.3 million non-redundant microbial genes (Eckburg et al., 2005; Gill et al., 2006;
Qin et al., 2010). On the other hand, some sites have more simple bacterial communities,
like the healthy vagina, which is mainly composed of Lactobacillus (Ravel et al., 2011).
These differences in community structure are likely a result of evolutionary pressures that
select for specific organisms able to adapt to a particular niche. This highlights the
different functional capacities of these microbes across various body sites.

1.2.1

Influence of the microbiota on health and disease

The bacterial communities that colonize various parts of our body are important in
promoting health whether it be by synthesizing vitamins the host cannot make, salvaging
energy from indigestible compounds, creating a competitive environment to prevent
pathogen colonization, promoting maturation and regulation of the immune system,
contributing to vascular development and angiogenesis or enhancing the integrity of the
epithelial barrier (Hyun et al., 2015; Mazmanian et al., 2005; Ragupathy et al., 2014;
Rakoff-Nahoum et al., 2004; Stappenbeck et al., 2002).
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The human microbiota in healthy individuals contains a collection of (i) symbionts,
which are bacteria that actively promote health, (ii) commensals, which are neither
advantageous nor detrimental to the host and (iii) pathobionts, which can promote
pathology when conditions are altered in the host (Round and Mazmanian, 2009). When
there is microbial disruption, either by reduction of symbionts and/or an overgrowth of
pathobionts, a breakdown in homeostasis will occur, leading to disease. This has been
observed in periodontitis (Darveau, 2010; Ximénez-Fyvie et al., 2000), inflammatory
bowel disease (Frank et al., 2007), psoriasis (Gao et al., 2008), asthma (Hilty et al.,
2010), bacterial vaginosis (Hummelen et al., 2010) and colorectal cancer (Mira-Pascual et
al., 2014). These changes are not simply a consequence of the diseased state creating an
environment that selects for certain bacteria, as studies have shown that healthy animals
transplanted with feces from those with obesity, colitis and colorectal cancer then go on
to develop disease (Garrett et al., 2007; Turnbaugh et al., 2009; Zackular et al., 2013).
These shifts in bacterial profiles not only have consequences at the site of origin but can
have distal site effects as well. For example, alterations in the gut microbiota can have
effects on the brain (Bercik et al., 2011; Cryan and Dinan, 2012), liver (Boursier and
Diehl, 2015; Yoshimoto et al., 2013) and pancreas (Larsen et al., 2010), while microbial
shifts in the oral cavity can be detrimental to cardiovascular health (Ettinger et al., 2014).
The human microbiota undergoes dramatic changes during the first year of life at which
time it becomes more stable and reflects what the community structure of the adult will
be. Thus, the bacteria acquired during infancy, influences the adult microbiota, which in
turn influences disease risk in adulthood (Guaraldi and Salvatori, 2012). For this reason,
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early life factors that shape the human microbiota play a critical role in health and
disease.

1.2.2

Early life factors that shape our microbiota

1.2.2.1

Mode of delivery

As early as 5 min after birth, newborns become colonized with a plethora of bacteria.
Unlike adults, whose bacterial composition is structured by body habitat, the microbiota
of the newborn is believed to be somewhat uniform across body sites (Dominguez-Bello
et al., 2010) until about 3 months of age (Capone et al., 2011). While traditional dogma
is that we are all born germfree, the discovery of bacteria in the healthy placenta
(Aagaard et al., 2014), amniotic fluid (DiGiulio et al., 2008), umbilical cord blood
(Jiménez et al., 2005) and meconium (Gosalbes et al., 2013) suggests that microbial
contact could occur in utero. However, a more complex community is acquired during
the birthing process and is largely influenced by mode of delivery. Vaginally delivered
babies have microbial profiles similar to that of their mother’s vaginal and fecal
microbiota, while those born by cesarean section have profiles similar to that of their
mother’s skin (Bäckhed et al., 2015; Dominguez-Bello et al., 2010). Infants born by Csection are more often colonized with Clostridium, have lower levels of Bacteroides and
acquire Bifidobacterium and Lactobacillus later than vaginally delivered infants
(Biasucci et al., 2008; Grönlund et al., 1999; Penders et al., 2006). These microbial
differences and the consequential immune responses associated with them can last
anywhere from 6 months to 7 years of age (Grönlund et al., 1999; Jakobsson et al., 2013;
Salminen et al., 2004).
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1.2.2.2

Breast feeding

In addition to bacteria acquired during the birthing process, the ingestion of fresh human
milk is a major source of microbes for the newborn (Martín et al., 2003, 2012). A
characteristic of breast fed infants is a gut microbiota dominated by Bifidobacterium.
Formula fed infants on the other hand harbour more diverse taxa dominated by
Enterobacteriaceae, Streptococcus, Bacteroides and Clostridium (Bezirtzoglou et al.,
2011; Favier et al., 2002). While the high abundance of Bifidobacterium in the gut of
breast fed infants is partly due to its ability to utilize human milk oligosaccharides
(HMOs) as an energy source (Sela et al., 2008), Bifidobacterium originating from milk
also contribute to its prevalence, as low levels in milk correlate to low levels in the
neonate (Grönlund et al., 2007).

1.3 Human milk microbiota
Human milk is generally the first food given to newborns and while the average amount
consumed varies with age, one study has shown that 15 week old infants ingest
approximately 788 ml of milk per day (Kent et al., 2006). The composition of human
milk consists of various fats, proteins, minerals, vitamins, sugars, bioactive compounds,
antibodies, immune cells, chemokines/cytokines, anti-microbials and growth factors
which all contribute to optimal nutrition, protection and development of the infant
(Ballard and Morrow, 2013). Bacteria also contribute in a significant way to the overall
make-up of human milk, with the microbiological content routinely recorded as high as
1x105 colony-forming units (CFU) per milliliter (Mense et al., 2014). The earliest studies
describing bacterial diversity in human milk utilized simple culture methods and reported
high levels of staphylococci and streptococci, originally believed to be contaminants
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(Eidelman and Szilagyi, 1979; West et al., 1979). Since then, numerous studies using
both culture and non-culture methods have detected a plethora of bacterial species in
human milk, which are no longer considered contaminants, but normal constituents in the
overall composition.
The first non-culture analysis of human milk started in the mid-2000s with the use of
denaturing gradient gel electrophoresis and 16S rRNA gene clone library analysis,
followed by the first deep sequencing analysis in 2011. These studies confirmed what
was observed by culture but also showed a greater diversity of bacteria in milk (Hunt et
al., 2011; Martín et al., 2007). While the milk microbiota varies greatly among women,
common constituents appear to be Staphylococcus and Streptococcus (in high
abundance), Corynebacterium and Propionibacterium and at lower levels, Lactobacillus
and Bifidobacterium. A list of all the bacteria identified in human milk to date, is
presented in Table 1-1.

1.3.1

Importance of milk bacteria in neonatal and long term
health

It is widely accepted that breast milk is far superior than formula for optimal physical,
psychological and immunological development of the newborn. The World Health
Organization recommends exclusive breastfeeding for 6 months, followed by another 2
years of partial breastfeeding, supplemented with solid foods. Infants fed human milk
compared to formula have lower incidences of necrotizing enterocolitis and diarrhea in
infancy and allergies, asthma, inflammatory bowel disease, type 1 and type II diabetes,
obesity and cardiovascular disease in adulthood (Guaraldi and Salvatori, 2012; Stuebe,
2009) as well as better cognitive function throughout life (Anderson et al., 1999). This
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protective effect may be due, in part, to the types of bacteria present in milk, as infants
fed formula supplemented with probiotics were better protected against some of the
above diseases than those just fed formula (Chouraqui et al., 2008; Guaraldi and
Salvatori, 2012; Silvers et al., 2012).
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Table 1-1. Bacteria identified in human milk by both culture dependent and
independent techniques.
Genera
Acinetobacter
Akkermansia
Bifidobacterium

Species
A. calcoaceticus
A. muciniphilia
B. breve, B. adolescentis, B. bifidum, B. longum, B. animalis,
B. catenulatum
Enterococcus
E. faecalis, E. faecium, E. durans, E. gallinarum, E. mundtii,
E. hirae
Escherichia
E. coli
Gemella
G. haemolysans
Klebsiella
K. oxytoca
Kocuria
K. kristinae
Lactobacillus
L. animalis, L. brevis, L. crispatus, L. fermentum, L. gasseri,
L. oris, L. plantarum, L. rhamnosus
Lactococcus
L. lactis
Leuconostoc
L. citreum, L. fallax, L. mesenteroides
Pediococcus
P. pentosaceus
Propionibacterium
P. acnes, P. granulosum
Pseudomonas
P. synxantha, P. fluorescens
Rothia
R. mucilaginosa
Serratia
S. proteomaculans
Staphylococcus
S. aureus, S. epidermidis, S. haemolyticus, S. hominis,
S. pasteuri, S. warneri
Streptococcus
S. salivarius, S. mitis, S. gallolyticus, S. australis,
S. vestibularis, S. parasanguis, S. pneumoniae
Weisella
W. cibaria, W. confusa
Other genera detected but not assigned to species
Actinomyces, Bacteroides, Blautia, Bradyrhizobium, Brevundimonas, Burkholderia,
Clostridium, Corynebacterium, Flavobacterium, Granulicatella, Prevotella, Rlastonia,
Sphingomonas, Stenotrophomonas, Veillonella
Data taken from: (Albesharat et al., 2011; Cabrera-Rubio et al., 2012; Collado et al.,
2009; Grönlund et al., 2007; Heikkila and Saris, 2003; Hunt et al., 2011; Jost et al., 2013;
Khodayar-Pardo et al., 2014; Martín et al., 2003, 2007; Solís et al., 2010)
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1.3.2

Where do breast milk bacteria come from?

Until recently, it was generally believed that bacteria in human milk originated from the
skin surrounding the nipple or from the oral cavity of the infant as a result of retrograde
backflow during suckling (Ramsay et al., 2004). However, the presence of obligate
anaerobes and species associated with the gut, respiratory tract and vagina would suggest
additional mechanisms.
This begs the question then, as to what other mechanisms could be responsible for
bacterial homing to the breast? Mucosal surfaces are defined as areas of the body exposed
to the external environment with a single layer of epithelial cells protecting the lumen
from the rest of the body. The mammary glands, along with the GIT, respiratory tract,
urogenital tract and glandular tissue (salivary, lacrimal) are considered mucosal surfaces
with their own specialized immune system that maintains homeostasis (McGhee and
Fujihashi, 2012). It has long been recognized that there is a common mucosal system that
allows for trafficking and homing of immune cells between mucosal sites. This has been
established through studies showing that (i) immunization at one mucosal site confers
protection at another mucosal site (Weisz-Carrington et al., 1979; Wilson and Obradovic,
2014) and that (ii) adoptive transfer of lymphoblasts from the mesenteric lymph nodes
(MLN) or bronchial lymph nodes (BLN) into syngeneic recipients home to other mucosal
surfaces such as the breast, bronchus, cervix and gut (McDermott and Bienenstock,
1979). It was also shown in the 1970s that cells isolated from the MLN would
preferentially home to the breast during lactation (Roux et al., 1977) which is probably
due the increased expression of CCL28 during this time (Meurens et al., 2006; Wilson
and Butcher, 2004). CCL28 is a chemokine expressed on mammary epithelial cells,
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responsible for the recruitment of IgA plasmoblasts and T cells to the mammary glands
from the gut or the airways (Lazarus et al., 2003; Wang et al., 2000). This migration and
homing of cells from the GIT and the respiratory tract to the breast has been termed the
entero-mammary and bronchial-mammary pathway respectively.
While these entero-mammary and bronchial-mammary pathways are important in
delivering antigen specific immune cells to the immunologically immature infant in order
to provide passive immunity against gastrointestinal and respiratory infections, it could
also be a mode by which bacteria migrate to the mammary glands. Indeed, during
pregnancy and lactation, increased numbers of bacteria have been detected in the
mammary glands compared to virgin mice with these bacteria co-localizing with
dendritic cells (Donnet-Hughes et al., 2010). This transfer of bacteria from the GIT to the
breast would explain the commonality of strains between a mother’s faeces and her breast
milk (Albesharat et al., 2011; Jost et al., 2014) and the detection of probiotic strains in
human milk after oral ingestion (Arroyo et al., 2010; Jiménez et al., 2008) (Figure 1-2).

1.3.2.1

Does trafficking occur in the “resting” breast?

Trafficking of bacteria via dendritic cells to the mammary glands has only been proposed
in the context of pregnancy and lactation but the fact that immune cells still migrate to the
mammary glands in non-gravid and non-lactating women suggests that bacterial
translocation to the breast could be happening continuously throughout a woman’s life.
VCAM-1, expressed on mammary epithelial cells, is responsible for B cell migration to
the breast during pregnancy (Low et al., 2010). However it is also expressed at high
levels irrespective of pregnancy and lactation and it is the main mechanism by which
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mouse mammary tumour virus infected lymphocytes reach the non-lactating/non-gravid
gland from the gastrointestinal tract (Finke and Acha-Orbea, 2001). High proportions of
intralobular B cells and luminal deposits of IgA have also been observed in breast tissue
of non-gravid/non-lactating women (Brandtzaeg, 1983; Drife et al., 1976). Most
importantly, dendritic cells, which have been the proposed vehicle for bacterial transfer
from the GIT to the mammary gland, are present in high numbers in breast lobules of
non-lactating/non-pregnant women (Degnim et al., 2014).
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Figure 1-2. Possible mechanism of bacterial translocation from the gut to the breast
The lumen of the gut is inhabited by trillions of bacteria and is separated from the interior
by a thin layer of cells called the epithelium. DCs can sample bacteria directly from the
lumen by the extension of dendrites or can capture bacteria that have translocated across
specialized epithelial cells called ‘M cells.’ DCs laden with bacteria can either prime T
cells in the Peyer’s patches or migrate to the MLN to prime T-cell reactions there. Unlike
primed T cells, DCs do not normally move past the MLN. However, during pregnancy
and lactation, it is believed that bacteria-laden DCs migrate out of the MLN and into the
mammary glands. These glands are composed of approximately 15–20 lobes that circle
around the nipple, albeit not as definitively visible during surgery as depicted in this
diagram. Inside these lobes are lobules and at the end of each lobule are tiny alveoli that
produce milk. The milk is carried via the ducts into the nipple. DC: Dendritic cell; MLN:
Mesenteric lymph node. Figure taken from (Urbaniak et al., 2012)
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1.4 Human microbiome and breast cancer
While the breast (via milk) is so vital to the health of the offspring, ironically, it is the
cause of one of the deadliest cancers in women. In Canada alone, it is estimated that by
the end of this year, 25,400 women will be diagnosed with breast cancer with 5,000 of
them dying from the disease (Canadian Cancer Society, 2016). To put into perspective,
this equates to 68 women being diagnosed and 14 women dying each day. Based on
current trends, it is predicted that these numbers will increase rather than decrease over
the next 20 years.
The etiology of breast cancer is still unknown but thought to be due to a combination of
both genetic and environmental factors. Support for environmental factors comes from
migration studies showing an increased incidence of breast cancer amongst migrants and
their descendants, after they move from a region of low breast cancer risk to a region of
high risk (Le et al., 2002; Shimizu et al., 1991). While many environmental predictors
have been proposed, such as smoking and diet, one factor not considered at the time of
entrance into my PhD program, was the potential of microbes, specifically in the breast,
to influence the risk of breast cancer development. The rationale for this idea is presented
below.

1.4.1

Causative role
development

of

bacteria

in

breast

cancer

Almost 40 years ago, it was reported that the spontaneous rate of various tumour
formations, over a 10 -year period, was higher in conventional rats compared to germfree ones, with mammary tumours being the second most common tumour recorded
(Sacksteder, 1976). The role of bacteria in mammary carcinoma was again delineated a
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few years later, when it was shown that conventional rats had an increased risk of
mammary tumours compared to germ free ones after sub-cutaneous injection with the
carcinogen, 3,2'-dimethyl-4-aminobiphenyl (DMAB) (Reddy and Watanabe, 1978).
One mechanism by which bacteria may contribute to disease onset is through production
of carcinogenic compounds from dietary components. Numerous studies using germ-free
and conventional animals have shown that risk-related components of the human diet
interact with the gut microbiota to induce DNA adducts and colon cancer (Hambly et al.,
1997; Reddy et al., 1975; Rumney et al., 1993). One of these risk-related dietary
components,

PhIP

(2-Amino-1-methyl-6-phenylimidazo[4,5-b]pyridine),

has

been

detected in the milk of lactating rats and human milk (DeBruin and Josephy, 2002; Scott
et al., 2007).
Another mechanism by which bacteria may promote breast cancer is through chronic
inflammation, which is now widely accepted to be associated with the development of
cancer (Mantovani et al., 2008). The effect of pathogen-induced inflammation is however
not limited to the site of infection. It has been shown that C57BL/6 ApcMin/+ mice, which
are genetically predisposed to develop mammary carcinomas, fail to develop disease
when housed under specific pathogen free conditions (Moser et al., 1993) but upon
gastric administration of Helicobacter hepaticus they develop mammary adenosquamous
carcinoma as a result of innate immune induction of inflammation (Rao et al., 2006a,
2006b).
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1.4.2

Protective role
development

of

bacteria

in

breast

cancer

Certain bacteria have properties that may reduce the risk of breast cancer development.
An epidemiological study conducted in The Netherlands involved 323 women showed
that the incidence of breast cancer decreased in women who drank fermented milk
products, irrespective of multivariable risk factors such as smoking, obesity, age of first
pregnancy, parity and alcohol consumption (van’t Veer et al., 1989). In vivo and in vitro
studies further support the protective role of lactic acid bacteria in breast cancer
development. An in vitro study showed that milk fermented with separate strains of lactic
acid bacteria (Bifidobacterium infantis, B. bifidum, B.animalis, Lactobacillus acidophilus,
L.paracasei) had an anti-proliferative effect on the MCF7 breast cancer cell line (Biffi et
al., 1997). In vivo, it has been shown that mice fed milk fermented with Lactobacillus
helveticus R389, display delayed or absent tumour growth compared to those that did not
receive the probiotic (de Moreno de LeBlanc et al., 2005). These protective effects were
proposed to be due to immune modulation by Lactobacillus, specifically a reduction in
IL-6 and an increase in IL-10 cytokine levels. Lactobacillus and Bifidobacterium have
also been shown to increase the percentage of activated natural killer (NK) cells in
peripheral blood mononuclear cells (PBMC) (Chiang et al., 2000; Takeda and Okumura,
2007). This could be beneficial, as women with breast cancer have impaired NK cell
function compared to healthy controls (Piroozmand and Hassan, 2010), which is
associated with an increased risk of breast cancer development (Imai et al., 2000; Strayer
et al., 1984).
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1.4.3

Bacteria in the breast and their role in breast cancer
development

The studies described above present a rationale for how distally located bacteria may
contribute to disease progression or prevention. Below I discuss the possible role of
bacteria within the breast in modulating this risk.
In a large scale analysis of 140,000 women in 47 studies from 30 different countries it
was shown that for every 12 months of breast-feeding the risk of breast cancer decreased
by 4.3% (Collaborative Group on Hormonal Factors in Breast Cancer, 2002). This study
did not account for the different molecular subtypes of breast cancer, but another
international study, conducted to assess the role of breast feeding in hereditary cancer,
showed that women with BRCA1 mutations who breast fed for 1 year or longer had a
45% reduced risk of breast cancer, though these protective effects were not seen in
patients with BRCA2 mutations (Jernström et al., 2004; Tryggvadottir et al., 2003).
Interestingly, an in vivo model with Caveolin-3-/- mice, which have constitutive milk
production, showed that mutants were substantially more protected against mammary
tumour development than their wild-type counterparts, after tumour injection (Sotgia et
al., 2009).
There are many theories as to why lactation could be protective, such as reduction of
estrogen levels (Jernström et al., 2004; Lyons et al., 2009), excretion of carcinogens from
the breast and differentiation of mammary epithelial cells (Lipworth et al., 2000).
Hormone modulation, however, may not be a significant contributor, as breast-feeding is
protective in estrogen receptor negative, progesterone receptor negative (ER-PR-) and
triple negative tumours (Gaudet et al., 2011; Ursin et al., 2005).
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We raise the possibility that bacteria present in the mammary glands during lactation
could act independently or in concert with other factors to afford protection. In a study
comparing the immunomodulatory potential of two species of Lactobacillus isolated from
breast milk (L. fermentum CECT5716 and L. salivarius CECT5713) with two non-milk
derived species (L. fermentum NCIMB7017511 and L. salivarius NCIMB11795) it was
shown that the milk-derived strains induced higher levels of IL-10 and activated NK cells
from PBMC (Pérez-Cano et al., 2010), two factors that are protective against breast
cancer. Possibly, the strains of bacteria growing in breast milk have been selected to
provide an evolutionary advantage to women to help control and/or prevent the
progression of breast cancer. This will be a difficult hypothesis to prove but one worthy
of consideration.

1.5 High-throughput sequencing to analyze the human
microbiota
The first description of microbes was reported in 1673 by the Dutch scientist Antonie van
Leeuwenhoek, with his work considered to be the start of the field of Microbiology.
Another pivotal landmark was the development of solid media by Robert Koch in 1881,
which allowed him to isolate disease-causing organisms thereby determining the agents
responsible for tuberculosis, cholera and anthrax. While culture analysis is routinely used
in labs across the world and has been indispensable to microbiologists over the last 130
years, culture methods have limited our understanding of the composition and function of
complex microbial communities, as most organisms cannot be grown in the lab (Amann
et al., 1995; Stewart, 2012). It is for this reason, that culture-independent methods, most
notably high throughput sequencing (HTS), has revolutionized the field of microbial
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ecology, allowing us to study the human microbiota and its function at various body sites,
in healthy and diseased patients and at different stages of human development (Coburn et
al., 2015; Costello et al., 2013; Gill et al., 2006; Grice et al., 2009; Human Microbiome
Project Consortium, 2012; Hummelen et al., 2010; Hunt et al., 2011; Koenig et al., 2011;
Macklaim et al., 2013; Turnbaugh et al., 2009; Wolfe et al., 2012).

1.5.1

16S rRNA gene targeted sequencing

The 16S rRNA gene is part of the small ribosomal subunit of bacteria, an evolutionary
conserved, ubiquitous molecule, that makes it useful for phylogenetic studies (Woese and
Fox, 1977). While 16S rRNA gene amplicon sequencing is the most popular method to
identify and compare bacteria within samples, some groups have opted to utilize other
targets, such as cpn60 (Links et al., 2012).
HTS has allowed for the unprecedented ability to process 100-1000s of samples at a time,
generating millions of reads at a reasonable cost, however, it is limited by the length of
sequence it can produce and the resolution of the phylogenetic assignment. The current
version of the Illumina MiSeq platform generates a maximum read length of 600bp, up
from 100bp when it was first developed. Because of this, HTS studies do not sequence
the full 16S rRNA gene (1.5kb) but specific regions of it, called hypervariable regions.
These hypervariable regions (V1-V9), flanked by conserved regions from which
amplification primers are designed, are as effective as the full length version at assigning
taxonomy and estimating community richness (Andersson et al., 2008; Gloor et al., 2010;
Liu et al., 2007).
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Currently there is no consensus in the field as to which hypervariable region should be
sequenced, because the “best one” will depend on the sequencing platform, databases
used for assigning taxonomy and the type of samples used (Soergel et al., 2012). Stool
microbiota studies typically use V4 or V3-V5 (which span the V4 region). V3, V4 and
V4/V5 have been shown to be more accurate in determining taxonomy compared to V2,
V5 alone and V6, regardless of sequencing platform (454 and Illumina MiSeq) or
database used to assign taxonomy (i.e. RDP, Greengenes, NCBI) (Claesson et al., 2010;
Huse et al., 2008; Liu et al., 2008; Mizrahi-Man et al., 2013). However, in terms of
estimating diversity (in the stool), all regions tested performed equally well (Liu et al.,
2008). Since V4 can detect a broad range of bacteria and archaea it has been chosen as
the target for the Earth Microbiome Project (www.earthmicrobiome.org). V6 is commonly
used in vaginal microbiota studies as it can differentiate Lactobacillus species, which
dominate the healthy vagina, as well as picking up the various organisms found in
women with bacterial vaginosis (Gloor et al., 2010).
V6 was the region of choice for the milk and tissue studies described herein, because
unlike primers for the V4 region, it does not cross-react with eukaryotic mitochondrial
DNA (personal observations and also noted in (Huys et al., 2008)). In stool samples,
where there is a higher proportion of bacterial vs eukaryotic DNA this is not a problem.
But in tissue, where eukaryotic DNA predominates, amplification needs to be as specific
as possible so as to not saturate the reads with eukaryotic sequences. In addition, V6 but
not V4 directed primers, detect Propionibacterium (Kuczynski et al., 2012) a common
skin organism that we expected to be present in our samples.
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In order to more readily interpret the massive amount of data generated with HTS, 16S
rRNA gene sequences that are similar to each other are clustered together into operational
taxonomic units (OTUs) which can then be used to estimate microbial diversity (Chen et
al., 2013; Schloss and Westcott, 2011). This is based on the assumption that sequences
that are similar to each other represent organisms that are more phylogentically related
(He et al., 2015). Sequences are typically clustered into OTUs with 97% similarity
(considered the threshold for separating species)(Schloss and Handelsman, 2005), with
the most abundant sequence in that group being the representative one used for
taxonomy. A table of OTUs and counts for each sample is then used for downstream
analysis such as beta diversity (diversity between samples), alpha diversity (diversity
within a sample) and comparing relative abundances between groups.

1.6 Scope and objectives
The Human Microbiome Project (HMP), funded by the National Institutes of Health, was
developed in order to comprehensively characterize the presence and function of bacteria
colonizing different body sites, under different conditions. This initiative, and a similar
one in Europe, was undertaken because of the overwhelming evidence showing how
important microbes can be in maintaining health and how significant aberrations can lead
to detrimental outcomes (Peterson et al., 2009). Phase 1 of the project was published in
2012 and reported the diversity of bacterial communities from 242 healthy American
adults (males and females) from 15-18 body sites (Human Microbiome Project
Consortium, 2012). Unfortunately and surprisingly, this large-scale study did not include
analysis of human milk.
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While there were milk microbiota studies prior to the HMP and others conducted after its
2012 publication, most of these utilized culture, denaturing gradient gel electrophoresis
and/or PCR specific amplification. At the start of this thesis there had only been 1 human
milk microbiota study utilizing HTS to characterize its composition (Hunt et al., 2011)
and none to determine what factor(s) could shape this bacterial community.
My first objective was thus to characterize the human milk microbiota in Canadian
women and to determine what factors shape its composition. In Chapter 2, I present a
case report following a woman over 4 months for Hodgkins lymphoma to determine how
drugs given distally could affect the milk microbiota- in this case we looked at the effects
of

the

ABVD

chemotherapeutic

regime

(adriamycin,

bleomycin,

vinblastine,

dacarbazine). In Chapter 3, I look at the effects of common pregnancy related factors
and its impact on the milk microbiota- specifically gestation (pre-term vs term birth),
mode of delivery (cesarean vs vaginal) and gender of the child (male vs female vs twins).
Considering that milk is not sterile, that there is exposure of the nipple to the external
environment and that the nutrient rich fatty environment of the breast could support
bacterial growth, I hypothesized that breast tissue, irrespective of lactation and
pregnancy, could also have its own indigenous microbiota. My second objective was thus
to characterize, using HTS and culture, the bacteria in breast tissue. In Chapter 4, I
present our findings from tissue samples analyzed from women from two distant
demographics: Canada (n=43) and Ireland (n=39).
After showing that a breast microbiome exists, my third objective was to examine
whether this microbiome could have a role in the development of breast cancer. The first
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aim within this objective was to determine whether bacterial profiles differ between
women with breast cancer and those who are disease free (Chapter 5). The rationale for
this comes from studies showing differences in microbial profiles between healthy
individuals and those with colorectal cancer, with these differences driving disease
development. The second aim within this objective was to explore how the breast
microbiota could promote disease progression. I did this by looking at the ability of
bacteria isolated from breast cancer patients to induce DNA damage using the γH2AX
assay (Chapter 5) and by sequencing the genome of a Bacillus cereus strain isolated
from a women with stage III invasive breast cancer (Chapter 6). Bacillus cereus was
chosen for this analysis as Bacillus species were higher in cancer patients compared to
controls and they were the most abundant organism cultured from breast cancer patients.
In a series of Appendices, I describe my work showing (i) the optimization of DNA
extraction protocols for low biomass samples, (ii) histological work to try and identify
where in the breast bacteria were located and lastly (iii) the properties of Lactobacillus
rhamnosus GR-1 (a probiotic) when grown in bovine milk, with an emphasis on a
pathway involving breakdown of lactosylceramide to ceramide, a pro-apoptotic signaling
molecule involved in controlling aberrant cell growth.
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Chapter 2

2

Effect of chemotherapy on the microbiota
metabolome of human milk, a case report

and

This chapter has been reproduced with permission (Appendix 8.6) from:
Urbaniak, C., McMillan, A., Angelini, M., Gloor, G.B., Sumarah, M., Burton, J.P., and
Reid, G. (2014). Effect of chemotherapy on the microbiota and metabolome of human
milk, a case report. Microbiome 2, 24.
A summary of clinical data (Dataset 2-1) and metabolites detected in human milk
(Dataset 2-2) is available for download online.

2.1 Introduction
Colonization of the neonatal gut plays a pivotal role in gastrointestinal, immunological
and neurological development with one of the initial sources of bacteria coming from the
mother’s milk (Martín et al., 2003, 2012). Breast fed infants have been shown to have
lower incidences of asthma, diarrhea, and necrotizing enterocolitis (NEC) compared to
formula fed infants (Stuebe, 2009). This protective effect may be due, in part, to the types
of bacteria present in milk, as infants fed formula supplemented with probiotics were
better protected against these conditions compared to those just fed formula (Chouraqui
et al., 2008; Guaraldi and Salvatori, 2012; Silvers et al., 2012). The bacteria acquired
during infancy can influence disease risk later in life and play a major role in what the
composition of the adult microbiome will be (Guaraldi and Salvatori, 2012). Thus,
factors that affect the milk microbiota have important health consequences for the child
not only during development but also into adulthood. In addition to the microbiota, the
metabolites of human milk, such as fatty acids, carbohydrates, proteins and vitamins also
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play an important role in infant development and long term health (Agostoni, 2008;
Boudry et al., 2010; German et al., 2002; Kunz et al., 2000).
Post delivery, many women are prescribed pharmaceutical agents for various reasons.
While most over the counter drugs and antibiotics are not contraindicated during breast
feeding (Donaldson and Goodchild, 2012; U.S. National Library of Medicine), when it
comes to chemotherapeutics, the recommendation is that breastfeeding should be avoided
until the drug has been cleared from the milk (Gartner et al., 2005). In a case report of a
70mg infusion of cisplatin, no detectable levels were found in milk after 66hr (Hays et
al., 2013) and in another case study using doxorubicin (trade name Adriamycin), no
detectable levels were seen after 72hr (Pistilli et al., 2013). In our particular study, the
subject was advised that breastfeeding could resume 12 days after each chemotherapy
session.
Here we present the first report on the effects of chemotherapy on microbial and
metabolomic profiles in human milk over a 4 month period in a breast feeding woman
undergoing treatment for Hodgkin’s lymphoma (Figure 2-1).

44

Figure'1'
Clinical'Informa-on'
Diagnosed with
Hodgkin’s
lymphoma during
2nd trimester of
pregnancy
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chemotherapy at
29wks gestation
(3rd trimester)
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delivery, chemo
starts again. Milk
sample collection
starts for the
study

Two weeks
after the last
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Figure 2-1. Summary of sample collection
Milk samples were collected from a lactating woman undergoing chemotherapy for
Hodgkin’s lymphoma. Milk samples were collected every two weeks over a 4-month
period. At each session milk was collected 15-30min before (“A”) and after (“B”)
chemotherapy. Duration of chemotherapy treatment lasted 2hr. No milk was collected at
week 8 due to scheduling conflicts.
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2.2 Methods
2.2.1

Clinical samples and study design

Ethical approval was obtained from Western Research Ethics Board and Lawson Health
Research Institute, London, Ontario, Canada. Subjects provided written consent for
sample collection and subsequent analyses.

2.2.2

Milk collection and processing

Mature milk was collected from a lactating woman undergoing the ABVD chemotherapy
regime (A=Adriamycin (40mg), B=Bleomycin (16 units), V= Vinblastine (9.6mg), D=
Dacarbazine (600mg) for Hodgkin’s lymphoma at the London Health Sciences Center,
London, Ontario. Mature milk was also collected from 8 healthy women recruited from
London, Ontario and the surrounding area. Wearing sterile gloves the women cleaned
their nipple and surrounding area with sterile saline swabs to reduce the presence of skin
bacteria. Milk was collected using a sterile HygieniKit Milk Collection System (Ameda)
attached to an electric breast pump. Between 5-15mL of milk was pumped into a sterile
tube and kept on ice until transfer to the laboratory which occurred within 1 hour of
collection. Samples were aliquoted and stored at -20oC until DNA extraction.

2.2.3

DNA isolation

After thawing on ice, 2 mL of milk were spun down at 13,000g for 10min and the
supernatant discarded. The pellet was then homogenized in 1.4mL of ASL buffer
(QIAamp® DNA Stool Kit, Qiagen) and 400mg of 0.1mm diameter zirconium-glass
beads (BioSpec Products). Mechanical and chemical lyses were performed by bead
beading at 4800rpm for 60s, then 60s on ice (repeated twice) (mini-beadbeater-1,
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BioSpec Products) and then incubated at 95oC for 5min. Subsequent procedures were
performed using the Qiagen QIAamp® DNA Stool Kit according to the manufacturer’s
protocol, with the exception of the last step in which the column was eluted with 120µL
of elution buffer. DNA was stored at -20oC until further use.

2.2.4

Ion Torrent V6 16S rRNA sequencing

2.2.4.1

PCR amplification

Genomic DNA isolated from the clinical samples, was amplified using the barcoded
primers,V6-LT:
5’CCATCTCATCCCTGCGTGTCTCCGACTCAGNNNNNCWACGCGARGAACCTTACC3’

and V6-RT: 5’CCTCTCTATGGGCAGTCGGTGATACRACACGAGCTGACGAC 3’, which
amplify the V6 hypervariable region of the 16S rRNA gene. The PCR was carried out in
a 40µL reaction containing 5µL of DNA template (or nuclease free water as a negative
control), 1.5mM MgCl2, 0.8µM of each primer, 4µL of 10x PCR Buffer (Invitrogen),
0.2mM dNTPs, 0.05U Taq Polymerase (Invitrogen) and 0.15µg/µL of bovine serum
albumin. Thermal cycling was carried out in an Eppendorf Mastercyler under the
following conditions: Initial denaturation at 95oC for 2min followed by 25 cycles of 95oC
for 1min, 55oC for 1min and 72oC for 1min. After amplification, the DNA concentration
was measured with the Qubit® 2.0 Fluorometer (Invitrogen) using the broad range assay.
Equimolar amounts of each PCR product were pooled together and purified using the
QIAquick PCR purification kit (Qiagen). The PCR purified sample was then sent to the
London Regional Genomics Center, London, Ontario, Canada for V6 16S rRNA
sequencing using the Ion Torrent platform as per the Center’s standard operating
procedure.
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2.2.4.2

Sequence processing and taxonomic assignment

Custom Perl and Bash scripts were used to de-multiplex the reads and assign barcoded
reads to individual samples. Reads were kept if the sequence included a perfect match to
the barcode and the V6 16S rRNA gene primers. Reads were clustered by 97% identity
into Operational Taxonomic Units (OTUs) using UClust v. 3.0.617 (Edgar, 2010). OTUs
that represented ≥1% of the reads in at least one sample were kept, while those that did
not meet the cut-off were discarded. Taxonomic assignments for each OTU were made
by the ribosomal database project (RDP) SeqMatch tool (Cole et al., 2009). From the top
20 matches to the RDP named isolates database, the full taxonomy was retained for
matches with the highest S_ab score. For multiple top matches with equal scores, the
highest common taxonomy was retained (e.g. genus level if multiple species matched
equally well). Since the maximum number of matches displayed per sequence is 20, the
RDP taxonomic assignments were verified by BLAST against the Greengenes named
isolates database with an output of 100 hits (DeSantis et al., 2006). Taxonomy was
assigned based on hits with the highest % identities and coverage. If multiple hits
fulfilled this criterion, classification was re-assigned to a higher common taxonomy. In
instances where the highest % identity/coverage yielded a single match, if this were less
than 90% and the S_ab score from RDP was less than 0.7, taxonomy was assigned at the
Family level instead of at the Genus level. The raw sequencing reads generated in this
study have been deposited to the NCBI Short Read Archive (SRA) database
(SRP041626).
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2.2.4.3

Data analysis

Weighted UniFrac distances were calculated in QIIME (Caporaso et al., 2010) by using a
phylogenetic tree of OTU sequences built with FastTree (Price et al., 2009) and based on
an OTU sequence alignment with MUSCLE (Edgar, 2004). The QIIME pipeline was also
used to calculate Shannon’s diversity index (logarithms with base 2) and to generate
principal coordinate analysis (PCoA) plots. Weighted UniFrac distances compare
microbial profiles (presence/absence and abundance) between samples (i.e. betadiversity) (Lozupone and Knight, 2005) while Shannon’s diversity index evaluates the
microbial diversity within a sample (i.e. alpha diversity). The higher the Shannon’s
diversity index, the more diverse a sample is and a value of zero indicates the presence of
only one species (Hill et al., 2003). PCoA plots allows one to visualize the UniFrac
distance matrix and plots the values on a set of orthogonal axes which capture the
greatest amount of variation between all samples tested. For beta-diversity analyses, the
data set was rarified to the lowest read count/sample, which was 734 reads. A summary
of clinical data, including total number of sequence reads per sample is shown in Dataset
2-1. Barplots, boxplots and stripcharts were all generated in R (https://www.rproject.org).

2.2.4.4

Statistical analysis

The ALDEx R package version 2 (Fernandes et al., 2014) was used to compare genera
between the non-treatment and chemotherapy treatment groups (as portrayed in the
boxplots). Microbiome data represents proportional distributions and are thus not
independent of each other. This means that a decrease in one organism will inevitably
lead to a concomitant increase in another organism. For example, if a sample has two
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organisms A (50%) and B (50%) and A is completely killed by an antibiotic, the
proportion of B in that sample will now be 100% even if its actual abundance has not
changed. The ALDEx R package estimates the technical variation inherent in highthroughput sequencing by Monte-Carlo sampling from a Dirichlet distribution (Jaynes,
2003). The Monte-Carlo replicates are transformed using the centered log-ratio
transformation that takes the logarithm of the Monte-Carlo estimates of organism
abundances in each sample divided by the per-sample geometric mean organism
abundance (Aitchison and Egozcue, 2005). This transformation has several desirable
properties that do not exist in proportional data, notably, subcomposition coherence and
linear sample independence. Data transformed in this way permit the use of standard
statistical tests to determine significance. Values reported in this manuscript represent the
expected values of 128 Dirichlet Monte-Carlo instances. A value of zero indicates that
organism abundance is equal to the geometric mean abundance. Thus organisms more
abundant than the mean will have positive values and those less abundant than the mean
will have negative values. Base 2 was used for the logarithm, thus differences between
values represent fold changes. Statistical significance for these comparisons was
determined by a Mann Whitney U test with p<0.05 and a false discovery rate of <0.1
using the q values output by the fdrtool R package. The unpaired student’s t-test was used
to compare Shannon’s diversity index (p<0.05).

2.2.5

GC-MS sample preparation

To extract metabolites 100µL of milk were mixed with 400µL pure methanol. Samples
were vortexed for 15s and centrifuged for 10 min at 9000g. Supernatants (200µL) were
transferred to GC-MS vials and 2.5µL of ribitol solution (2mg/ml) was added to each vial
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as an internal standard. Samples were dried to completeness using a SpeedVac. After
drying, 100µL of 2% methoxyamine•HCl in pyridine (MOX) was added to each sample
for derivitization and samples were incubated at 50oC for 90 min. N-Methyl-N(trimethylsilyl) trifluoroacetamide (MSTFA) (100µL ) was then added to each vial and
incubated at 50oC for 30 min. Samples were transferred to microinserts before running on
GC-MS (Agilent 7890A GC, 5975 inert MSD with triple axis detector, 30m DB5-MS
column with 10m duraguard column). Samples were run using 1µL injections on scan
mode and a solvent delay of 10 min. Run time was 60 min per sample. Each sample was
run twice non-consecutively to ensure consistency throughout the sequence.

2.2.5.1

Data analysis for GC-MS

Chromatogram files were converted to ELU format using the AMDIS Mass Spectrometry
software (Stein, 1999). Chromatograms were aligned and abundance of metabolites
calculated using the Spectconnect software (Styczynski et al., 2007) with the support
threshold set to low. In order to determine if differences between week 0 and
chemotherapy (weeks 2-16) existed, principle component analysis (PCA) was conducted
in SIMCA (Umetrics) using the relative abundance matrix (RA) output from
Spectconnect. Data were mean centered and pareto scaled prior to PCA. Independent
unpaired t-tests with Bonferroni correction were calculated in Excel to determine
metabolites that were significantly altered by chemotherapy (p < 0.05.). Compounds that
also contributed to the separation of week 0 from chemotherapy samples according to the
PCA loadings plot (compounds in bottom left quadrant) were chosen for further
investigation.
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2.3 Results
Chemotherapy affected both bacterial diversity and bacterial profiles in human milk.
Bacterial diversity within samples was lower in milk collected throughout chemotherapy
compared to milk samples collected at week 0 and from healthy lactating women (Figure
2-2). Bacterial profiles at week 0 were similar to those from healthy women, however this
changed within 2 weeks of treatment (Figure 2-3A). Samples collected at weeks 4-16
shared similar profiles and differed from week 2 and from week 0/healthy samples
(Figure 2-3A). These differences were not due to natural changes over time, as the
bacterial community in two milk samples analyzed from a healthy subject did not change
over a four-month period (Figure 2-3A, green samples). The bar plot in Figure 2-3B
shows the bacterial communities present in these samples with a striking increase in
abundances of Acinetobacter and Xanthomonadaceae in milk collected during
chemotherapy.

A

comparison

of

relative

abundances

of

Acinetobacter,

Xanthomonadaceae and Stenotrophomonas (a genus part of the Xanthomonadaceae
family) between the chemotherapy (week 4-week 16) and non-treatment (week 0 and
healthy samples) groups are displayed in Figure 2-4 and were shown to be significantly
higher during chemotherapy. We also examined the differences between three bacteria
believed to confer beneficial health effects to the infant, Bifidobacterium, Eubacterium
and Lactobacillus. The first two were significantly decreased during chemotherapy
whereas no differences were observed for Lactobacillus (Figure 2-4). Overall, a total of
22 out of the 49 genera identified were differentially abundant between the two groups
(Table 2-1).
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Figure 2-2. Changes in bacterial diversity as a result of chemotherapy
Bacterial diversity within a sample (i.e alpha diversity) was measured by calculating
Shannon’s diversity index. Each point on the graph represents a subject with the line
representing the mean for all samples within a group. The higher the index the greater the
bacterial diversity found within a sample. The mean of the “Wk0/H” group (week0 and
healthy samples) was 4.3, and that of the “Chemotherapy” group (week 4-16) was 2.8.
Groups were statistically different from each other as measured by unpaired student’s ttest (p <0.05).
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Figure 2-3. 16S rRNA sequencing analysis of bacteria in human milk
Milk samples were collected from a lactating woman undergoing chemotherapy as
described in Figure 2-1 as well as from 8 healthy lactating women. (A) Weighted
UniFrac principal coordinates analysis (PCoA) plot. Each milk sample, represented by a
coloured circle, is plotted on this 3D, 3 axis plane representing 84% of the variation
observed between all samples. Samples that cluster together are similar in biota
composition and abundance. Orange circles represent samples collected from weeks 4-16
of chemotherapy, blue circles represent samples collected at week 2 of chemotherapy,
purple circles represent samples collected at week 0, red circles represent milk samples
from healthy lactating women (only one time point) and green circles represent milk
samples collected from a healthy lactating women collected 4 months apart. As shown by
the plot, there were 3 distinct groups: (i) week 0 samples and healthy milk samples; (ii)
week 2 of chemotherapy and (iii) weeks 4-16 of chemotherapy. Data were rarified to 735
reads/sample. (B) Barplot showing the relative abundance of different genera in each
sample. Each bar represents a subject and each coloured box a different genus. The height
of the coloured boxes represents the relative abundance of that genus within the sample.
Genera that were less than 2% abundant in a given sample were placed in the “Remaining
fraction” at the top of the graph (grey boxes).
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Figure 2-4. Comparison of relative proportions of bacterial taxa between groups
Boxplots comparing 6 bacterial taxa between samples collected during chemotherapy
(week 4-16) and those without treatment (week 0 and healthy samples, “Wk0/H”). The
box signifies the 75% (upper) and 25% (lower) quartiles and thus shows where 50% of
the samples lie. The black line inside the box represents the median. The whiskers
represent the lowest datum still within 1.5 IQR of the lower quartile and the highest
datum still within 1.5 IQR of the upper quartile (IQR= interquartile range). Outliers are
shown with open circles. The value “0” represents the geometric mean abundance, thus
values above 0 are more abundant and values less than 0 are less abundant than the
geometric mean. Significant differences were observed between the two groups for all
taxa graphed (Mann Whitney U test p<0.05, FDR <0.1).
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Table 2-1. Comparison of relative abundances of different genera detected in milk
between the chemotherapy and non-treatment groups
Values in the second and third columns represent the base 2 logarithm of the median
abundance in all samples within a group (that is, Wk0/H samples (non-treatment group)
or Chemo (treatment group)) relative to the geometric mean abundance, which has a
value of 0. Thus, positive values are higher than the geometric mean and are thus more
abundant than negative values, which are lower than the geometric mean. Significant
differences were based on FDR values of <0.1. Out of the 49 genera identified, 22 were
significantly different between the two groups

57

Taxa
Acinetobacter
Gammaproteobacteria
Stenotrophomonas
Xanthomonadaceae
Cloacibacterium
Rhizobiales
Porphyrobacter
Thermus
Streptococcus
Flavobacterium/Cytophaga
Bifidobacterium
Eubacterium
Rothia
Brevundimonas/Caulobacter
Microbacteriaceae
Staphylococcus
Anoxybacillus/Bacillus
Bacillus
Gammaproteobacteria OTU11
Petrobacter
Truepera
Betaproteobacteria
Enterobacteriaceae
Sphingomonas
Faecalibacterium
Tepidimonas
Comamonadaceae
Schlegelella
Pseudomonas
Finegoldia
Bacteroidetes
Prevotella
Legionella
Corynebacterium
Sphingobium/Sphingomonas
Porphyromonas
Rhizobium/Agrobacterium
Ruminococcus
Flavobacteriaceae
Gemella
Peredibacter
Sphingobacterium
Atopobium
Methylophilus
Brevundimonas
Gardnerella
Propionibacterium
Lactobacillus
unclassified Bacteria

Wk0/H
5.542
4.372
-3.181
0.605
5.301
-1.947
2.763
-2.361
2.313
0.169
0.74
0.224
-1.221
3.105
-1.449
4.445
1.616
0.243
3.729
0.184
2.9
2.579
3.204
0.939
-0.361
0.662
1.21
1.058
3.494
-2.234
-3.188
-3.061
-2.686
-1.075
1.136
-3.614
1.212
-3.541
-3.811
-2.353
-2.9
-2.283
-3.526
-3.242
1.479
-2.188
2.103
0.891
5.004

Chemo
10.88
7.901
5.751
8.547
1.981
2.541
0.259
1.733
4.696
3.062
-3.51
-3.607
2.325
-0.117
1.322
2.306
3.53
2.623
0.3
-2.054
-0.271
-0.119
5.026
2.103
-2.055
-2.512
2.257
-1.364
4.771
-4.213
-5.058
-5.022
-4.538
-2.789
-1.244
-5.246
-0.374
-4.725
-5.116
-0.957
-4.141
-3.517
-3.942
-1.833
0.797
-2.203
2.182
1.273
4.489

p-value
0
0
0
0.001
0.001
0.001
0.001
0.002
0.001
0.002
0.002
0.003
0.002
0.003
0.006
0.008
0.007
0.008
0.017
0.025
0.026
0.026
0.036
0.047
0.055
0.048
0.064
0.067
0.098
0.186
0.248
0.227
0.271
0.235
0.21
0.306
0.23
0.36
0.346
0.375
0.423
0.476
0.552
0.517
0.483
0.637
0.721
0.837
0.874

FDR value
0
0.001
0.002
0.003
0.003
0.003
0.005
0.006
0.007
0.007
0.008
0.01
0.011
0.013
0.022
0.028
0.029
0.03
0.052
0.076
0.081
0.093
0.123
0.139
0.156
0.159
0.195
0.251
0.359
0.42
0.463
0.467
0.554
0.569
0.584
0.611
0.632
0.642
0.642
0.766
0.768
0.781
0.867
0.879
0.918
0.933
0.954
0.993
1

Higher in
Chemo
Chemo
Chemo
Chemo
Wk0/H
Chemo
Wk0/H
Chemo
Chemo
Chemo
Wk0/H
Wk0/H
Chemo
Wk0/H
Chemo
Wk0/H
Chemo
Chemo
Wk0/H
Wk0/H
Wk0/H
Wk0/H
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
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The metabolic profile also changed as a result of chemotherapy (Figure 2-5) and was
similar between week 2-16, but different to that observed at week 0. A total of 226
metabolites were detected by our GC-MS method, 12 of which were significantly
different between the week 0 and chemotherapy (week 2-16) groups (Table 2-2). Dataset
2-2 shows the relative abundance of all metabolites detected in milk.

Table 2-2. Metabolites significantly altered by chemotherapy
(*) metabolite identity confirmed by authentic standards. Chemotherapy refers to samples
collected from week 2-16. Significant differences were determined using the unpaired
student’s t-test, p < 0.05.
Metabolite

Elevated in

unknown PUFA
DHA *
arabinose
threitol
unknown
unknown
decanoic acid
myristic acid
1-monopalmitin
butanal
unknown
Inositol *

week 0
week 0
chemotherapy
chemotherapy
chemotherapy
chemotherapy
chemotherapy
chemotherapy
chemotherapy
chemotherapy
chemotherapy
week 0

Bonferroni corrected
p value
1.81E-07
0.000304
0.000456
0.001342
0.002685
0.002768
0.008458
0.008727
0.009143
0.012356
0.017961
0.037225

Figure"5"

59

A"

B"

Figure 2-5. Principal component analysis of metabolites in breast milk at week 0
and during chemotherapy
(A) Scoreplot displaying the distribution of samples based on metabolites alone, where
the distance between samples represents how similar the metabolome of those samples
are. Each point represents the average of 2 technical replicates. (B) Loadings plot. Each
point represents a metabolite. Metabolites present in a given quadrant of the loadings plot
are present in highest abundance in samples present in the same quadrant of the scoreplot
(A).

60

2.4 Discussion
This study has shown that a course of chemotherapy has significant effects on bacterial
and metabolic profiles in human milk, moving away from those of healthy lactating
women. Of note, the subject did not report any additional drug use, antibiotics, illness or
major changes in diet over the course of the study.
The consequences of decreased bacterial diversity in human milk and the implications on
the child are still unknown however the decreased milk diversity could impact intestinal
diversity and it has been shown that low intestinal diversity in the first weeks of life has
been associated with necrotizing enterocolitis (Mshvildadze et al., 2010) and an increased
risk of allergy and atopy in school age children (Madan et al., 2012). Lower intestinal
diversity has also been observed in children with type 1 diabetes compared to age
matched controls (Giongo et al., 2011).
In addition to overall changes in microbial profiles, we observed a significant decrease in
the relative abundance of Bifidobacterium in the chemotherapy group compared to the
non-treatment group. Bifidobacterium is the predominant organism in the gut of breast
fed infants, attributed to its ability to metabolize the human milk oligosaccharides (HMO)
present in large amounts in milk (Sela et al., 2008; Asakuma et al., 2011). Maternal levels
have also been shown to impact gut Bifidobacterium abundance, with low levels in milk
correlating with low levels in the neonatal gut (Grönlund et al., 2007). The potential
consequences of decreased numbers of Bifidobacterium being passed on from the mother
to the neonate could be an increased risk of asthma or obesity later in life. High levels of
Bacteroides have been reported in the gut of infants with low levels of Bifidobacterium
(Jost et al., 2012) and early colonization with high Bacteroides counts has been attributed
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to an increased risk of developing asthma and obesity (Vael et al., 2008, 2011a, 2011b).
In addition, depleted levels of Bifidobacterium have been shown to promote colonization
of opportunistic pathogens such as Klebsiella and Citrobacter (Jost et al., 2012).
Staphylococcus, including coagulase negative species, are one of the predominant
organisms in human milk (Hunt et al., 2011; Jost et al., 2013; Ward et al., 2013) and were
also significantly reduced as a result of chemotherapy. It has been shown that numerous
human milk isolates of Staphylococcus epidermidis can inhibit the growth of
Staphylococcus aureus (Heikkila and Saris, 2003), the main causative agent of mastitis, a
painful inflammatory condition of the breast, that often leads to pre-mature cessation of
breastfeeding in many women. While we were not able to identify the Staphylococcus in
our samples down to the species level with 16S rRNA gene sequencing, culture analysis
on mannitol salt agar plates did show that the Staphylococcus isolates were not S.aureus
and the select few that were tested were coagulase negative. This reduction of
Staphylococcus (likely coagulase negative species) as a result of chemotherapy could
make lactating women more prone to infections, affecting both themselves and their
infants. Like Bifidobacterium, Staphylococcus is passed from the milk to the neonate,
with higher numbers in the intestine of breastfed compared to formula fed infants (Martín
et al., 2012). Interestingly, a metagenome analysis revealed the presence of
immunosuppressive motifs in bacterial DNA from human milk, with the majority of these
belonging to Staphylococcus (Ward et al., 2013). The exposure of the neonate to this
DNA, either ingested from the milk or through live bacteria that have released their DNA
once in the gut, could help to regulate the immune response against a variety of
innocuous bacterial, environmental and food antigens.
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The utilization of bacterial products by other bacteria is termed metabolic cross-feeding
and plays an important role in bacterial selection. For example, the byproducts of
bacterial metabolism such as lactate and acetate production are utilized as an energy
source by many butyrate producing bacteria (Barcenilla et al., 2000; Belenguer et al.,
2006; Duncan et al., 2004a, 2004b) such as Eubacterium, which was decreased in our
chemotherapy group. Butyrate is important for health, as it reduces inflammation and
metabolic diseases, promotes colonic repair and protects against colon cancer (Hamer et
al., 2008; Lin et al., 2012). On the other hand some pathogens persist and cause disease
only in the presence of certain commensal bacteria (Ramsey et al., 2011), likely due to
the metabolites produced. Thus changes in bacterial communities in human milk will
inevitably alter the metabolic milieu, selecting for bacteria able to utilize those
metabolites. As a result, potential shifts from a healthy and balanced intestinal microbiota
can occur, having important consequences on health.
Docosahexaenoic acid (DHA), inositol and an unknown poly-unsaturated fatty acid
(PUFA) were among the 12 metabolites that differed between week 0 and weeks 2-16,
with reduced levels detected during chemotherapy (weeks 2-16). DHA is the most
abundant long chain PUFA in the brain, retina and nerve cells and is supplied mainly
through breast milk (Morse, 2012). DHA deficiencies lead to reduced brain, eye and
neuronal development (Morse, 2012) and it has been observed that breastfed infants have
better visual acuity and neuronal development compared to those fed formula (Hoffman
et al., 2009). Reduced levels of DHA and alpha-linolenic acid (a precursor of DHA) have
been reported in milk of mothers with atopic children compared to milk from mothers
with non-atopic children (Duchén et al., 2000; Yu et al., 1998). Another principal
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metabolite in the neonatal brain is inositol and is important for osmoregulation, cellular
nutrition and detoxification (Kok et al., 2001). Palmitic acid levels were also reduced
during chemotherapy, though the results were not significant. Palmitic acid is the most
abundant lipid in human milk and has been shown to increase bone strength in infants
(Litmanovitz et al., 2013) and limit intestinal damage and pro-inflammatory immune
responses in mice (Lu et al., 2013). While changes in metabolite concentrations do occur
over the course of lactation, especially between colostrum and mature milk, no changes
in the above metabolites over the course of the first year of life have been detected in
mature milk (Jóźwik et al.; López-López et al., 2002; Marangoni et al., 2000; Ribeiro et
al., 2008). Due to the high variability in milk metabolites between individuals, we did not
have enough samples from healthy women to make substantive claims as to how the
Hodgkin’s patient compared, however, there were no obvious differences in the
metabolic profiles of control samples taken at early compared to later stages of lactation.
We recognize that the main limitation of the study is its single case study content of a
patient undergoing chemotherapy. However, the findings were revealing and warrant
further investigation into how more commonly prescribed drugs, such as antibiotics, may
effect the milk microbiota and if changes do occur, how long do these changes last.

2.5 Conclusion
The bacterial and metabolic composition in human milk, so critical for infant
development, can change significantly by maternal exposure to chemotherapeutic agents.
This study emphasizes the importance of conducting further studies to examine changes
in the microbiota and metabolomic as a result of drug intake in lactating mothers, and the
consequences of these changes to the long term health of the infant.
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Chapter 3

3

Human milk microbiota profiles in relation to birthing
method, gestation and infant gender

This chapter is reproduced with permission (Appendix 8.6) from:
Urbaniak, C., Angelini, M., Gloor, G.B., and Reid, G. (2016). Human milk microbiota
profiles in relation to birthing method, gestation and infant gender. Microbiome 4, 1.
Supporting Datasets 3-1 (clinical metadata), 3-2 (OTU annotations) and 3-3 (ALDEx2
summary) are available for download online as additional excel files

3.1 Background
With the incidence of various non-infectious diseases on the rise, there is much interest in
the developmental origins of health and disease and the potential role of early life feeding
practices in modulating these outcomes. Breast fed infants have been shown to be better
protected than formula fed infants against necrotizing enterocolitis and diarrhea, allergy
and asthma, inflammatory bowel disease, type 1 and type II diabetes, obesity and
cardiovascular disease (Guaraldi and Salvatori, 2012; Stuebe, 2009). In addition to
immune protection and bioactive compounds being conveyed through maternal milk, a
possible protective role of bacteria has been suggested. Lower than average levels of
Bifidobacterium in human milk correlate with low levels of Bifidobacterium in the
neonatal gut (Grönlund et al., 2007), allowing for higher than normal levels of
Bacteroides to be established (Jost et al., 2012). These high levels of Bacteroides early in
life have been associated with an increased risk of asthma and obesity later in life (Vael
et al., 2008, 2011a, 2011b). Indeed, efforts to manipulate the microbiota of formula fed
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infants through probiotic supplementation have resulted in protection against some of the
above diseases, comparable to that observed for breast fed infants (Chouraqui et al.,
2008; Dilli et al., 2015; Kankaanpää et al., 2002).
Differences exist in bioactive components, macronutrients, cytokines, enzymes, proteins
and immunological factors between Pre-term vs Term milk and milk from mothers giving
birth by vaginal vs cesarean deliveries (Dizdar et al., 2014; Koenig et al., 2005; Mehta
and Petrova, 2011a, 2011b; Wang et al., 2014; Zanardo et al., 2001). As well, the energy
content differs in milk depending on gender of the newborn, with breast milk from
mothers who give birth to sons having more fat content than that of daughters (Fujita et
al., 2012; Powe et al., 2010).
We hypothesized that physiological or hormonal triggers that influence milk composition
might also support different bacterial genera. Thus, we studied human milk samples from
women giving birth at different stages of gestation, by vaginal or caesarian delivery, and
examined whether gender of the newborn also affected the microbiota profiles.

3.2 Methods
3.2.1

Milk collection and processing

A single milk sample (Day 6 and onwards post partum) was collected from 39 Caucasian
Canadian women recruited from London, Ontario and the surrounding area, representing
a homogenous community (Dataset 3-1, metadata). Even though the samples collected
were from different days after birth, with some considered “transitional” and others
“mature,” a Kendall’s Tau correlation test showed no statistically significant correlation
between OTU relative abundances over time after a Benjamini-Hochberg correction for
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multiple hypothesis tests. This shows that it is acceptable to use all milk samples,
regardless of when it was collected, in our analyses.
Ethical approval was obtained from Western Research Ethics Board and Lawson Health
Research Institute, London, Ontario, Canada. Subjects provided written consent for
sample collection and subsequent analyses. Participants were excluded if they were
suffering from mastitis and were/had been on antibiotics during lactation. Cesarean
deliveries were classified as either (i) “non-elective”; if there were complications during
labour or (ii) “elective”; if they were planned in advance or if the health of the fetus
and/or mother was at risk prior to labour.
Wearing sterile gloves the women cleaned their nipple and surrounding area with sterile
saline swabs to reduce the presence of skin bacteria. Milk was collected using a sterile
HygieniKit Milk Collection System (Ameda, Buffalo Grove, IL, USA) attached to an
electric breast pump. Between 5 and 15 ml of milk was pumped into a sterile tube and
kept on ice until transfer to the laboratory, which occurred within 1 hour of collection.
Samples were aliquoted and stored at -20°C until DNA extraction.

3.2.2

DNA isolation

After thawing on ice, 2 ml of milk were spun down at 20,000  g for 10 minutes and the
supernatant discarded. The pellet was then homogenized in 1.4 ml of ASL buffer
(QIAamp® DNA Stool Kit, QIAGEN: Valencia, CA, USA) and 400 mg of 0.1 mm
diameter zirconium-glass beads (BioSpec Products, Bartlesville, OK, USA). Mechanical
and chemical lyses were performed by bead beading at 4,800 rpm for 60 s, then 60 s on
ice (repeated twice) using a mini-beadbeater-1 (BioSpec Products) and then incubated at
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95°C for 5 minutes. Subsequent procedures were performed using the QIAGEN
QIAamp® DNA Stool Kit according to the manufacturer’s protocol, with the exception
of the last step in which the column was eluted with 120 µl of elution buffer. DNA was
stored at -20°C until further use.
A no template PCR control and a DNA extraction kit reagent control were sequenced
alongside the samples. We observed that the taxon abundances in the controls were
uncorrelated with the abundances in the experimental samples, and the distance between
the controls and samples was large. Thus, we conclude that the controls had different
profiles than that of the milk samples (Figure 3-1).
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Figure 3-1. Principal components analysis biplot comparing milk samples with
controls.
To verify that the microbiota observed in our milk samples was not due to background
contamination from reagents in either the DNA extraction kit or from the PCR, a no
template PCR control (“NTC1”) and a tube of PBS that was extracted alongside the milk
samples (“reagent_control”) were sequenced. Data presented in the biplot are from
centered log ratio transformed values. As observed, the controls have a different
microbial profile than the milk samples.
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3.2.3

PCR amplification

The genomic DNA isolated from the clinical samples was amplified using barcoded
primers that amplify the V6 hypervariable region of the 16S rRNA gene which is 70 base
pairs long.
V6-Forward:
5’ACACTCTTTCCCTACACGACGCTCTTCCGATCTnnnn(8)CWACGCGARGAACC
TTACC 3’
V6-Reverse:
5’CGGTCTCGGCATTCCTGCTGAACCGCTCTTCCGATCTnnnn(8)ACRACACGAGCT
GACGAC 3’

nnnn indicates 4 randomly incorporated nucleotides and “8” represents a specific sample
barcode sequence. The PCR was carried out in a 42 µl reaction containing 2 µl of DNA
template (or nuclease-free water as a negative control), 0.15 µg/µl bovine serum albumin,
20µl of 2x GoTaq hot start colorless master mix (Promega) and 10µl of each primer
(initial concentration: 3.2pmol/µl). Thermal cycling was carried out in an Eppendorf
Mastercyler under the following conditions: initial denaturation at 95°C for 2 minutes
followed by 25 cycles of 95°C for 1 minute, 55°C for 1 minute and 72°C for 1 minute.
After amplification, the DNA concentration was measured with the Qubit® 2.0
Fluorometer (Invitrogen) using the broad range assay. Equimolar amounts of each PCR
product were then pooled together and purified using the QIAquick PCR purification kit
(QIAGEN). The pooled PCR purified sample was then paired-end sequenced on the
Illumina Mi-Seq platform using a 150 cycle kit with a 2x80 run at the London Regional
Genomics Center, London, Ontario, Canada following standard operating procedures.
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3.2.4

Sequence processing and taxonomic assignment

Custom Perl and Bash scripts were used to de-multiplex the reads and assign barcoded
reads to individual samples. Multiple layers of filtering were employed: (i) Paired end
sequences were overlapped with Pandaseq, allowing 0 mismatches in the overlapped
reads; (ii) Reads were kept if the sequence included a perfect match to the V6 16S rRNA
gene primers; (iii) Barcodes were 8mers with an edit distance of >4 and reads were kept
if the sequence were a perfect match to the barcode; (iv) Reads were clustered by 97%
identity into operational taxonomic units (OTUs) using the Uclust algorithm of
USEARCH v7 (Edgar, 2010) which has a de novo chimera filter built into it; (v) All
singleton OTUs were discarded and those that represented ≥1% of the reads in at least
one sample were kept.
Taxonomic assignments for each OTU were made by extracting the best hits from the
SILVA database (Pruesse et al., 2007) and then manually verified using the Ribosomal
Database Project (RDP) SeqMatch tool (rdp.cme.msu.edu) and by BLAST against the
Green genes database (greengenes.lbl.gov) Taxonomy was assigned based on hits with
the highest percentage identities and coverage. If multiple hits fulfilled this criterion,
classification was re-assigned to a higher common taxonomy. A summary of each OTU
classification and its sequence is shown in Dataset 3-2. The raw sequencing reads
generated in this study have been deposited to the NCBI Short Read Archive (SRA)
database accession # SRP 064311.

3.2.5

Data analysis

Weighted and un-weighted UniFrac distances (Lozupone and Knight, 2005) were
calculated in QIIME (Caporaso et al., 2010) by using a tree of OTU sequences built with
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FASTTREE (Price et al., 2009) based on an OTU sequence alignment made with
MUSCLE (Edgar, 2004). The QIIME pipeline was also used to generate principal
coordinate analysis (PCoA) plots to visualize the Bray-Curtis dissimilarity. Changes in
the microbial-community composition were also analyzed by calculating the generalized
UniFrac distance (alpha= 0.5, rooted phylogenetic tree) using the GUniFrac package in
R, version 3.1.2 (Chen et al., 2012). PERMANOVA was used to test for statistical
significance between the groups using 10000 permutations (QIIME package). Barplots,
boxplots, stripcharts, PCoA plots and k-means clustering analysis were all generated in R
(http://www.R-project.org/).
The ALDEx R package version 2 (Fernandes et al., 2014) was used to compare genera,
class, family and phyla between preterm vs term milk; cesarean vs vaginal deliveries and
male vs female child. Values reported in this manuscript represent the expected values of
128 Dirichlet Monte-Carlo instances. A value of zero indicates that organism abundance
is equal to the geometric mean abundance. Thus, organisms more abundant than the mean
will have positive values and those less abundant than the mean will have negative
values. Base 2 was used for the logarithm so differences between values represent fold
changes. Significance (p<0.05) was based on the Benjamini-Hochberg corrected p-value
of the Welch’s t test and the Wilcoxon test.

3.3 Results
Characterization of the milk microbiota in 39 Canadian women showed high variability
amongst women (Figure 3-2). Overall, the top 5 most abundant taxa represented in milk
were

Staphylococcus

(31%),

Enterobacteriaceae

(10%),

Pseudomonas

(17%),

Streptococcus (5%) and Lactobacillus (3%) (Figure 3-3). While there was variability
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amongst samples at the genus level, at higher taxonomic levels, profiles were consistent
amongst women with Proteobacteria and Firmicutes making up the highest proportion of
phyla in all samples with Actinobacteria and Bacteroidetes also present, but at lower
levels (Figure 3-4).
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Figure 3-2. Breast milk microbiota in 39 Canadian women identified by 16S rRNA
amplicon sequencing.
The relative abundances of bacterial genera in different human milk samples were
visualized by bar plots. Each bar represents a subject and each colored box a bacterial
taxon. The height of a coloured box represents the relative abundance of that organism
within the sample. Taxa present in less than 2% abundance in a given sample are
displayed in the “Remaining fraction” at the top of the graph (gray boxes). As shown by
the bar plots, a variety of bacteria were detected in breast milk. The legend is read from
bottom to top, with the bottom organism on the legend corresponding to the bottom
colored box on the bar plot.
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Figure 3-4. Percent abundance of bacterial phyla in breast milk identified by 16S
rRNA amplicon sequencing
(A) The relative abundances of different phyla in different breast milk samples were
visualized by bar plots. (B) Box plots of the four phyla identified in breast milk. The box
signifies the 75% (upper) and 25% (lower) quartiles and thus shows where 50% of the
samples lie. The black line inside the box represents the median. The whiskers represent
the lowest datum still within 1.5 interquartile range (IQR) of the lower quartile and the
highest datum still within 1.5 IQR of the upper quartile. Outliers are shown with open
circles. As shown, 4 phyla are represented in breast milk and present in all samples, with
Proteobacteria and Firmicutes being the most abundant.
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No differences were detected in microbial profiles based on gestation, mode of delivery
or gender of the child, using both weighted (Figure 3-5A) and un-weighted UniFrac
distances (data not shown). The above two matrices, however, assign a large emphasis on
either rare or highly abundant taxa, so compositional changes that occur in moderately
abundant lineages may be overlooked (Chen et al., 2012). For this reason, we also
analyzed the data using generalized UniFrac at an alpha of 0.5, which overcomes this
problem (Chen et al., 2012). As with weighted UniFrac, no differences were observed
based on gestation, mode of delivery or gender of the child (Figure 3-5B), but there was
separation of 13 samples, forming 2 distinct clusters, which could not be explained by
any of the other metadata that was collected (Figure 3-6). To further confirm the above
results, we also utilized the Bray-Curtis dissimilarity metric, which does not take into
account phylogenetic relatedness of the biological community, as does UniFrac. As
expected, no differences were observed (data not shown).
The dataset was also analyzed using ALDEx2 to examine whether specific taxa were
differentially expressed based on gestation, mode of delivery or gender. Again, no
differences were detected at the genus (Dataset 3-3), family, class or phyla levels (data
not shown).
Of interest, the abundance profiles clearly showed that mothers are transmitting very
different bacterial profiles to newborns. For example, the milk of subject 40 contained
over 80% abundance of staphylococci, whereas that of subject 25 comprised mostly
Gram negative organisms, especially Pseudomonas.
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Figure 3-5. Principal coordinate (PCoA) plots comparing bacterial profiles based
on gestation, mode of delivery and gender
PCoA plots based on (A) weighted UniFrac distances or (B) generalized UniFrac
distances at alpha 0.5. Each sample, represented by a coloured circle, is plotted on this
two-dimensional, 2 axis plane with the first 2 components plotted. Samples (points) that
cluster together are more similar in biota composition and abundance. As shown by the
plot, the lack of distinct clustering between groups, for Gestation (1st row), mode of
delivery (2nd row) and gender (3rd row), indicate that no bacterial differences exist
between pre-term vs term samples, cesarean vs vaginal delivery samples and male vs
female samples. PERMANOVA (p<0.5). P_ex=extremely pre-mature (gestation <28
weeks); P_very=very pre-mature (gestation 29-32wks); P_late=late pre-mature (gestation
33-36wks); T=Term (gestation >37wks). “c_E”= elective cesarean delivery; “c_NE”=
non-elective c-section; “v”=vaginal delivery. “m”= male child; “f”= female child;
“m_tw”= twins both male; “f_tw”= twins both female; “Twin”= male and female twins.
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Figure 3-6. Principal coordinate analysis based on generalized UniFrac distances.
Each sample, represented by a coloured circle, is plotted on this two-dimensional, 2 axis
plane with the first 2 components plotted. Samples (points) that cluster together are more
similar in biota composition and abundance. GUniFrac, using an alpha of 0.5 (which is
more sensitive to changes in moderately abundant taxa), was used to compare microbial
profiles based on gestation, mode of delivery and gender. While no differences were seen
based on these conditions, there were 3 distinct groups, which could not be explained by
any of the metadata collected (Dataset 3-1). The number of clusters was determined using
the k-means clustering analysis in R.
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3.4 Discussion
This study revealed a range of bacterial genera in human milk, consistent with previous
studies (Hunt et al., 2011; Jost et al., 2013; Urbaniak et al., 2012). Interestingly, even
when a baby was born extremely prematurely (subject S24), the mother’s milk was
similar in composition to that of a woman giving birth at full term (subject S30). It can be
speculated that this might be a failsafe mechanism whereby the mother is 'ready' to pass
along her bacterial imprint irrespective of when the baby is born. If so, the microbiota
would appear to be recalcitrant to late pregnancy hormonal and inflammatory changes,
which could indicate an evolutionary pressure protecting this niche for the baby's benefit.
Further studies on this concept are warranted, and cases where the milk profiles are very
different or the outcome for the baby negative, could be particularly insightful.
It was not surprising that milk from emergency C section deliveries (i.e. non-elective) did
not differ from women who gave birth vaginally, as this decision is made at the time of
labour, when the hormones and timing for birth have been initiated. We also did not see
differences between non-elective C section deliveries and vaginal births which is in
contrast to a study published by Cabrera-Rubio et al. in which they concluded that the
human milk microbiome is shaped by mode of delivery (Cabrera-Rubio et al., 2012).
However, we do not believe that the authors adequately proved this claim. In their
analysis the milk samples collected were from both obese and normal weight women
with no indication of the proportion in each group. Since it was shown in that same paper
that body mass index influences the milk microbiota, the subject’s weight could have
been a confounding factor responsible for the observed differences. In addition, the
author’s claim that the milk microbiota is influenced by mode of delivery was based
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solely on visual observations of barplots (that were not very distinct between the two
groups), with no PCoA plots or statistical analyses to support this claim. These
conflicting results between our group and that of Cabrera-Rubio highlights the need for
future studies with larger sample sizes and inclusion of women from various
demographics.
Because of the multivariate nature of the data, differences, if they are present, may have
been masked by the different variables confounding each other. Thus a larger sample size
allowing for linear regression analysis would strengthen our claims. However there is the
possibility that no matter the sample size, differences will only be apparent when
examined at the level of the individual. Schwarzberg et al. showed that treatment for
periodontitis had no effects on microbial profiles when compared to controls. However,
when pre and post treatment effects for each individual were compared, significant
changes in bacterial composition was observed. The authors thus emphasized the
importance of comparing shifts from a personalized healthy state to a personalized
disease state in order to truly understand biological changes (Schwarzberg et al., 2014).
Proteobacteria and Firmicutes were the dominant phyla, consistent with a previous highthroughput study performed in Switzerland and analyzed with a different sequencing
platform (454 sequencing) (Jost et al., 2013). The detection of Staphylococcus, as the
most abundant organism, is likewise consistent with other studies (Hunt et al., 2011; Jost
et al., 2013; Urbaniak et al., 2012). Staphylococcus is more abundant in the gut of breast
fed newborns compared to formula fed ones (Balmer and Wharton, 1989; Lundequist et
al., 1985) but their numbers start to decrease after the first week of life when oxygen has
been consumed and an environment favourable for anaerobes is created (Adlerberth,
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2008; Jost et al., 2012). Unlike Staphylococcus, which is present in high abundance in at
least the first week of life, Proteobacteria are never found in high numbers in the feces of
newborns, infants or Western adults (Human Microbiome Project Consortium, 2012; Jost
et al., 2012; Koenig et al., 2011) Thus, an important question arises, as to what the
evolutionary significance is of having such a diverse population of bacteria in milk, if
only a select few seem to colonize during the development of the neonate. There are a
few possibilities; firstly, persistent colonization is not always needed for beneficial
effects, as transient exposure can be just as effective (Gan et al., 2014; Hapfelmeier et al.,
2010). Secondly, bacteria in milk may not have to be passed on from mother to child to
exert their beneficial effects. Many of the protective factors in milk such as antibodies,
immune cells, lactoferrin and beta-defensins originate from the mammary gland and not
from the blood (Tunzi et al., 2000). With the ability of bacteria to regulate host gene
expression, such as anti-microbials, and their ability to stimulate the immune system, the
plethora of bacteria in breast milk could be inducing up regulation of these protective
factors in the breast that then get passed on in high concentrations to the neonate via
milk.
From another perspective, there is the possibility that some of these milk microbes have
either limited or no effects on the offspring but are present for the benefit of the mother,
such as in the protection against mastitis. Mastitis is a painful inflammatory condition of
the breast with the main causative agent being Staphylococcus aureus and it has been
shown that some milk commensals have the ability to prevent S. aureus growth and
infection (Heikkila and Saris, 2003). The same is true for a skin derived strain of
Propionibacterium acnes, which prevents growth of S.aureus via its byproducts of
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glycerol fermentation (Shu et al., 2013). With the high abundance of glycerol present in
milk, milk derived strains of Propionibacterium may have similar growth inhibiting
properties, which would account for its presence in every milk sample collected.
Lactobacillus was present in high abundance in milk, so for those women who deliver by
C section and thus do not transfer lactobacilli from the vagina to the infant, the milk
could provide a means for these beneficial organisms to reach the infant gut.

3.5 Conclusion
A diverse population of bacteria is present in breast milk dominated by the phyla
Proteobacteria

and

Firmicutes

and

the

taxa

Staphylococcus,

Pseudomonas,

Enterobacteriaceae, Streptococcus and Lactobacillus. While no differences in microbial
profiles were apparent based on gestation, mode of delivery or gender, more studies are
still needed on what factors do influence bacterial communities in milk and how these
changes impact neonatal and maternal health.
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Chapter 4

4

Microbiota of human breast tissue

This chapter is reproduced with permission (Appendix 8.6) from:
Urbaniak, C., Cummins, J., Brackstone, M., Macklaim, J.M., Gloor, G.B., Baban, C.K.,
Scott, L., O’Hanlon, D.M., Burton, J.P., Francis, K.P., Tangney, M., and Reid, G. (2014).
Microbiota of human breast tissue. Appl. Environ. Microbiol 80, 3007-3014.
Supporting Datasets 4-1 (clinical metadata) and 4-2 (taxonomic classification of OTU
sequences) are available for download online as additional excel files

4.1 Introduction
The human body is home to a large and diverse population of bacteria with properties
that are both harmful and beneficial to our health (Bäckhed, 2012; Hooper, 2004; Human
Microbiome Project Consortium, 2012; Macpherson and Harris, 2004; Serino et al.,
2009; Zhu et al., 2013) and for this reason there has been a strong push in recent years to
fully characterize the bacteria associated with different parts of the body under different
health conditions. These studies have been made possible with the use of deep
sequencing technologies and sites once thought of as sterile, such as the stomach, bladder
and lungs have now been shown to harbour an indigenous microbiota (Beck et al., 2012;
Bik et al., 2006; Wolfe et al., 2012). We hypothesized that microbes may also be present
in breast tissue given the known presence of bacteria in human milk (Urbaniak et al.,
2012). This is not surprising considering that skin and oral bacteria have access to the
mammary ducts through the nipple (Ramsay et al., 2004) with some recent studies
suggesting their source to be from the mother’s gastrointestinal tract (Donnet-Hughes et
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al., 2010). We rationalized that given the nutrient rich fatty composition of the female
breast, the widespread vasculature and lymphatics, and the diffuse location of the lobules
and ducts leading from the nipple, bacteria would be widespread within the mammary
glands, irrespective of lactation. Thus, the objective of the study was to determine, using
culture and non-culture methods, whether breast tissue contains a microbiome. To ensure
that the results obtained were not an artifact of a single demographic, tissue was collected
and processed from two distant countries, Canada and Ireland.

4.2 Materials and Methods
4.2.1

Clinical samples and study design (Canadian samples)

Ethical approval for this study was obtained from Western Research Ethics Board and
Lawson Health Research Institute, London, Ontario, Canada. Patients provided written
consent for sample collection and subsequent analyses.

4.2.1.1

Tissue collection and processing

Breast tissue was collected from 43 women (aged 18-90) undergoing breast surgery at St.
Joseph’s Hospital in London, Ontario, Canada. Thirty-eight of those women underwent
lumpectomies or mastectomies for either benign (n=11) or cancerous (n=27) tumours and
5 women underwent breast reductions and had no history of breast cancer. For those
women with tumours, the tissue obtained for analysis was collected outside of the
marginal zone, approximately 5cm away from the tumour. After excision, the fresh tissue
was immediately placed in a sterile vial on ice and homogenized within 30 min of
collection. As an environmental control, a tube filled with sterile phosphate buffered
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saline (PBS) was left open for the duration of the surgical procedure and then processed
in parallel with the tissue samples.
Tissue samples were homogenized in sterile PBS using a PolyTron 2100 homogenizer at
28000 rpm. The amount of PBS added was based on the weight of the tissue in order to
obtain a final concentration of 0.4g/ml. Fresh homogenate and the environmental controls
were then plated on different agar plates for culture analysis and the remaining amount
aliquoted and stored at -80oC until DNA extraction.

4.2.1.2

DNA isolation

After tissue homogenates were thawed on ice, 400µl (equivalent to 160mg of tissue) were
added to tubes containing 1.2ml of ASL buffer (QIAamp® DNA Stool Kit, Qiagen) and
400mg of 0.1mm diameter zirconium-glass beads (BioSpec Products). Mechanical and
chemical lyses were performed by bead beading at 4800rpm for 60s, then 60s on ice
(repeated twice) (mini-beadbeater-1, BioSpec Products) and then incubated at 95oC for
5min. Subsequent procedures were performed using the Qiagen QIAamp® DNA Stool
Kit according to the manufacturer’s protocol, with the exception of the last step in which
the column was eluted with 120µl of elution buffer. DNA was stored at -20oC until
further use.

4.2.2

Clinical samples and study design (Irish samples)

Ethical approval for this study was obtained from University College Cork Clinical
Research Committee. Patients provided written consent for sample collection and
subsequent analyses.
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4.2.2.1

Tissue collection and DNA isolation

Breast tissue was collected from 38 women (aged 20-85) undergoing breast surgery at
Cork University Hospital or South Infirmary Victoria Hospital, Cork, Ireland. Thirtythree women underwent lumpectomies or mastectomies for cancerous tumours (taken at
least 5cm away from the primary tumour site) while 5 women underwent breast
reductions and had no history of breast cancer. Once collected the specimens were placed
in sterile cryotubes and flash frozen in liquid nitrogen within 45 minutes of collection and
then stored at -800C until DNA extraction.
Tissue samples were thawed on ice and the genomic DNA extracted using the Gene-Elute
Mammalian Genomic DNA miniprep kit (Sigma-Aldrich) as per the manufacturer’s
protocol with the exception of the elution step, where the column was eluted with 70µl of
elution buffer.

4.2.3

Ion Torrent V6 16S rRNA sequencing

4.2.3.1

PCR amplification

At the Canadian lab, the genomic DNA isolated from Canadian and Irish clinical samples
was amplified using the barcoded primers V6-LT and V6-RT (see section 2.2.4.1 for
primer sequence), which amplify the V6 hypervariable region of the 16S rRNA gene. The
PCR was carried out in a 40µl reaction containing 5µl of DNA template (or nuclease free
water as a negative control), 1.5mM MgCl2, 0.8µM of each primer, 4µl of 10x PCR
Buffer (Invitrogen), 0.2mM dNTPs, 0.05U Taq Polymerase (Invitrogen) and 0.15µg/µl of
bovine serum albumin. Thermal cycling was carried out in an Eppendorf Mastercyler
under the following conditions: Initial denaturation at 95oC for 2min followed by 25
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cycles of 95oC for 1min, 55oC for 1min and 72oC for 1min. After amplification, the DNA
concentration was measured with the Qubit® 2.0 Fluorometer (Invitrogen) using the
broad range assay. Equimolar amounts of each PCR product were then pooled together
and purified using the QIAquick PCR purification kit (Qiagen). The PCR purified sample
was then sent to the London Regional Genomics Center, London, Ontario, Canada for V6
16S rRNA sequencing using the Ion Torrent platform as per the Center’s standard
operating procedure.

4.2.3.2

Sequence processing and taxonomic assignment

Custom Perl and Bash scripts were used to de-multiplex the reads and assign barcoded
reads to individual samples. Reads were kept if the sequence included a perfect match to
the barcode and the V6 16S rRNA gene primers and were within the length expected for
the V6 variable region. Samples with more than 600 reads were kept while those with
less than 600 were discarded. Reads were then clustered by 97% identity into Operational
Taxonomic Units (OTUs) using UClust v. 3.0.617 (Edgar, 2010). OTUs that represented
≥2% of the reads in at least one sample were kept, while those that did not meet the cutoff were discarded to account for the high error rate intrinsic to Ion Torrent sequencing.
Taxonomic assignments for each OTU were made by the Ribosomal database project
(RDP) SeqMatch tool (Cole et al., 2009). From the top 20 matches to the RDP named
isolates database, the full taxonomy was retained for matches with the highest S_ab
score. For multiple top matches with equal scores, the highest common taxonomy was
retained (e.g. genus level if multiple species matched equally well). Since the maximum
number of matches displayed per sequence is 20, the RDP taxonomic assignments were
verified by BLAST against the Greengenes named isolates database with an output of
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100 hits (DeSantis et al., 2006). Taxonomy was assigned based on hits with the highest %
identities and coverage. If multiple hits fulfilled this criterion, classification was reassigned to a higher common taxonomy. In instances where the highest %
identity/coverage yielded a single match, if this were less than 90% and the S_ab score
from RDP was less than 0.7, taxonomy was assigned at the Family level instead of at the
Genus level.

4.2.3.3

Data analysis

The QIIME pipeline (Caporaso et al., 2010) was used to (i) calculate weighted UniFrac
distances and Shannon’s diversity index (logarithms with base 2); (ii) summarize OTUs
by different taxonomic levels and (iii) generate Unweighted Pair Group Method with
Arithmetic Mean (UPGMA) trees representing hierarchical clustering of samples. The
UniFrac distances were calculated by using a phylogenetic tree of OTU sequences built
with FastTree (Price et al., 2009) and based on an OTU sequence alignment with
MUSCLE

(Edgar,

2004).

Weighted

UniFrac

compares

microbial

profiles

(presence/absence and abundance) between samples (i.e. beta-diversity) (Lozupone and
Knight, 2005) while Shannon’s diversity index evaluates the microbial diversity within a
sample (i.e. alpha diversity). The higher the Shannon’s diversity index, the more diverse
a sample is and a value of zero indicates the presence of only one species (Hill et al.,
2003). UPGMA trees allows one to visualize the distance matrix and the robustness of
what was observed was tested with jackknifing and bootstrapping. For beta-diversity
analyses, the data set was rarified to the lowest read count/sample. Barplots, boxplots and
stripcharts were all generated in R (http://www.R-project.org/).

100

4.2.4

Culture analysis

In an effort to prove that bacteria in the breast were viable, 100µl of Canadian tissue
homogenate from each of the 43 samples and 100µl of each environmental control were
plated on Columbia blood agar (CBA) plates and incubated aerobically or anaerobically
at 37oC. Of note, the facilities to perform culture were not available at the Irish site. DNA
from single colonies was extracted using the InstaGene Matrix (Bio-Rad) and then
amplified using the eubacterial primers pA/pH, which amplify the 16S rRNA gene:
pA 5’ AGAGTTTGATCCTGGCTCAG 3’ pH 5’ AAGGAGGTGATCCAGCCGCA 3’
The PCR reaction was carried out in 50µl reaction containing 10µl of DNA template (or
nuclease free water as a negative control), 1.5mM MgCl2, 1.0µM of each primer, 0.2mM
dNTP, 5µl 10X PCR buffer (Invitrogen), and 0.05 Taq Polymerase (Invitrogen). Thermal
cycling was carried out in an Eppendorf Mastercycler under the following conditions:
Initial denaturation step at 95oC for 2min, followed by 30 cycles of 94oC for 30s, 55oC
for 30s and 72oC for 1min. A final elongation step was performed at 72oC for 10min.
After running 10µl of the PCR mixture on a 1% agarose gel to verify the presence of
amplicons, 40µl of the PCR mixture was then purified using the QIAquick PCR
purification kit (Qiagen). The purified PCR products were then sent for Sanger
sequencing to the London Regional Genomics Centre, London, Ontario, Canada.
Sequences were analyzed using the GenBank 16S ribosomal RNA sequences database
using the BLAST algorithm (Altschul et al., 1990). Taxonomy was assigned based on the
highest Max score.
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4.2.5

Statistical analysis

Statistical analysis was performed in R using the Kruskal-Wallis one-way analysis of
variance followed by the Mann-Whitney U test with Bonferroni correction.

4.3 Results
Tissue was obtained from various locations within the breast, from close to the nipple to
as far back as the chest wall (Figure 4-1). Regardless of location sampled within the
breast, presence/absence of breast malignancy, country of origin, age, history of
pregnancy and method of DNA preparation, a variety of bacteria were detected in breast
tissue (Figure 4-2, Figure 4-3 and Dataset 4-1). Bacterial diversity within samples varied
between individuals with Shannon’s diversity indices ranging from 0.8-5.2, with an
average value of 3.6 (Figure 4-4). To put into perspective, using the same index, oral and
gut samples, known for their diverse bacterial communities have values between 3.9-6.5
(Bik et al., 2010; Dethlefsen and Relman, 2011; Dethlefsen et al., 2008; Li et al., 2012),
while vaginal samples of low bacterial diversity, generate values between 0.46-2.9 (Kim
et al., 2009; Oakley et al., 2008; Ravel et al., 2011).
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Figure 4-1. Location within the breast of tissue samples collected for analysis
Tissue samples were collected from 43 women from London, Canada and 38 women
from Cork, Ireland undergoing different breast surgeries. (A) and (B) Location of tissue
collected from women in Canada undergoing lumpectomies or mastectomies for either
malignant “LN” (A) or benign “LNb” (B) tumours. (C) Location of tissue collected from
women in Ireland undergoing lumpectomies or mastectomies for malignant tumours
“CN”. Blue ovals represent the location of the tumour and purple squares represent the
location of the specimen obtained for bacterial analysis. The distance between the blue
ovals and purple squares are approximate estimates of the distance between the tumour
and the specimen, which was at least 5cm away from the tumour. (D) Location of tissue
collected from women in both Canada and Ireland undergoing breast reduction surgery,
“LH” and “CH” respectively. Asterisks in the purple boxes underneath the subject
number indicate samples from Ireland. All samples were a minimum of 1cm deep to the
skin with the surgeons aiming for mid-deep rather than superficial. As shown in the
diagram, specimens were obtained from a variety of locations within the breast.
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Figure 4-2. Breast tissue microbiota in 43 Canadian women identified by 16S rRNA
sequencing
The relative abundance of bacterial taxa identified in different tissue samples was
visualized by bar plots. Each bar represents a subject and each coloured box, a bacterial
taxa. The height of the coloured boxes represents the relative abundance of that organism
within the sample. For example, sample L42H is dominated by Acinetobacter whereas
L19Nb is dominated by Micrococcus. Taxa present in less than 2% abundance in a given
sample are displayed in the “Remaining fraction” at the top of the graph (grey boxes). As
shown by the barplots, a variety of bacteria were detected in breast tissue. NB: The
legend is read from bottom to top, as indicated by the red arrow, with the bottom
organism on the legend, corresponding to the bottom coloured box on the barplot. “LH”=
Tissue collected from women undergoing breast reductions; “LN”= Non-malignant tissue
collected adjacent to cancerous tumours; “LNb”= Non-malignant tissue collected
adjacent to benign tumours.
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Figure 4-3. Breast tissue microbiota in 38 Irish women identified by 16S rRNA
sequencing
The relative abundance of bacterial taxa identified in different tissue samples was
visualized by bar plots. Each bar represents a subject and each coloured box, a bacterial
taxa. The height of the coloured boxes represents the relative abundance of that organism
within the sample. For example, sample C40H is dominated by Janibacter whereas C36N
is dominated by Enterobacteraceae. Taxa present in less than 2% abundance in a given
sample are displayed in the “Remaining fraction” at the top of the graph (grey boxes). As
shown by the barplots, a variety of bacteria were detected in breast tissue. NB: The
legend is read from bottom to top, as indicated by the red arrow, with the bottom
organism on the legend, corresponding to the bottom coloured box on the barplot. “CH”=
Tissue collected from women undergoing breast reductions; “CN”= Non-malignant tissue
collected adjacent to cancerous tumours

107

CH

CN

1.0

Remaining fraction
Bradyrhizobium
Actinomycetales
Paracoccus

0.8

Caryophanon
Myroides
Fusobacterium

Microbiota fraction

Methylobacterium

0.6

Burkholderia
Butyrivibrio
Corynebacterium
Faecalibacterium
Roseomonas

0.4

Porphyrobacter
Schlegelella
Finegoldia
Proteobacteria

0.2

Thiotrichaceae
unclassified
Lactococcus

C1N
C2N
C3N
C4N
C5N
C6N
C7N
C8N
C9N
C10N
C11N
C12N
C13N
C14N
C15N
C18N
C19N
C20N
C21N
C22N
C23N
C25N
C26N
C28N
C29N
C30N
C31N
C32N
C33N
C34N
C35N
C36N
C37N

Bacillales

C38RH
C39RH
C40H
C41RH
C42RH

0.0

Ochrobactrum
Salmonella
Aerococcus
Caulobacteraceae
Eubacterium
Microbacteriaceae
Succinivibrionaceae
Rubrobacter
Lactobacillus
Sphingomonas
Turicella
Streptococcus
Betaproteobacteria
Cloacibacterium
Comamonadaceae
Oxalobacteraceae
Lysobacter
Alloiococcus
Bacteria unclassified
Prevotella
Gammaproteobacteria
Pseudomonas
Bacillus
Janibacter
Acinetobacter
Propionibacterium
Listeria
Staphylococcus
Enterobacteriaceae

Figure 3

6

108

5

●
●

●●
●
●
●●
●● ● ● ● ●
●
●
●
●
●
● ●
●

●
●

●

4

●

●

●

●

●
●

●
●

●

●

●

●
●
●

●

● ●

●
●
●●

●

3

●●
●●

●

●
●
●●
● ● ●●
●
●
●
●

●
●
●
●

●

●

2

Shannon's diversity index

●

●

●
●

●

●
●

●

1

●

0

●
●

Canada

Ireland

Figure 4-4. Bacterial diversity of the breast tissue microbiota

Fig. S1. Bacterial diversity of the breast microbiota. Bacterial diversity within a sample (i.e.

Bacterial diversity within a sample (i.e. alpha diversity) was measured by calculating
alpha diversity) was measured by calculating Shannon’s diversity index. Each point on the graph

Shannon’s diversity index. Each point on the graph represents a subject with the line
represents a subject with the line representing the mean for all samples. The higher the index the

representing the mean for all samples. The higher the index, the greater the bacterial
greater the bacterial diversity found within a sample. Since Shannon’s diversity index is a

diversity found within a sample. Since Shannon’s diversity index is a logarithmic number
logarithmic number with a base of 2, a value of “4” is 2x higher than a value of “3”. The mean

with a base of 2, a value of “4” is 2x higher than a value of “3”. The mean value for the
value for the London samples was 3.9 (n=43) and for the Irish samples, 3.3 (n=33).

Canadian samples was 3.9 (N=43) and for the Irish samples, 3.3 (N=33).
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The bacteria identified in tissue were grouped into 121 operational taxonomic units
(OTUs) based on 97% sequence similarity (Dataset 4-2). These OTUs belonged to 7
different phyla; Proteobacteria, Firmicutes, Actinobacteria, Bacteroidetes, DeinococcusThermus, Verrucomicrobia and Fusobacteria with Proteobacteria being the most
abundant phylum followed by Firmicutes (specifically from the class Bacilli) (Figure 45). Of the 121 OTUs identified, 57 could be classified at the genus level and 25 at the
species level (Dataset 4-2). The most abundant taxa in the Canadian samples were
Bacillus (11.4%), Acinetobacter (10.0%), unclassified Enterobacteriaceae (8.3%),
Pseudomonas (6.5%), Staphylococcus (6.5%), Propionibacterium (5.8%), unclassified
Comamonadaceae (5.7%), unclassified Gammaproteobacteria (5.0%) and Prevotella
(5.0%). In the Irish samples the most abundant taxa were unclassified Enterobacteriaceae
(30.8%), Staphylococcus (12.7%), Listeria welshimeri (12.1%), Propionibacterium
(10.1%) and Pseudomonas (5.3%).
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Figure 4-5. Percent abundance of different bacterial phyla in breast tissue identified
by 16S rRNA sequencing
(A) Boxplots of the seven different phyla identified in breast tissue from the Canadian
and Irish samples. The box signifies the 75% (upper) and 25% (lower) quartiles and thus
shows where 50% of the samples lie. The black line inside the box represents the median.
The whiskers represent the lowest datum still within 1.5 IQR of the lower quartile and the
highest datum still within 1.5 IQR of the upper quartile (IQR= interquartile range).
Outliers are shown with open circles. (B) The least abundant phyla shown in (A) were
plotted on another graph with a smaller scale to allow for better visualization of
Figure 4

percentage. In samples from both countries Proteobacteria was the most abundant phyla
followed by Firmicutes (Kruskal-Wallis/Mann-Whitney U with Bonferroni correction, p
≤ 0.001).
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Of the 30 environmental controls (i.e. PBS tube processed in parallel with tissue sample)
sequenced on the Ion Torrent platform, 12 of them were discarded due to low read counts
(<600 reads). Of the remaining 18 controls that passed quality control filtering, 13 of
them had lower read counts than their respective tissue samples. Of the 6 with higher read
counts, weighted UniFrac UPGMA hierarchical clustering showed that microbial profiles
differed between the control and its respective tissue sample (Figure 4-6).
Bacteria were able to be cultured from all 43 of the Canadian samples (culture analysis
was not performed on the Irish samples) with amounts ranging from 75-2000 cfu/gram of
tissue, depending on the sample. Collectively, eight different strains were identified:
Bacillus

sp,

Micrococcus

luteus,

Propionibacterium

acnes,

Propionibacterium

granulosum, Staphylococcus sp, Staphylococcus saprophyticus, Streptococcus oralis,
Streptococcus agalactiae. No bacteria were isolated from any of the 43 environmental
controls.
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Fig. S2. UPGMA hierarchical clustering comparing Canadian tissue samples with their
respective environmental controls. UPGMA hierarchical clustering translates the UniFrac

Figure 4-6.
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together are more
similar in bacterial
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abundance) than those that are farther apart on the tree. Jackknifing and bootstrapping
environmental control is distinct. Reads were rarified to 475 reads/sample. “E”= environmental

were performed
measure
the robustness of these observations. The red coloured
control andto“N”=
tissue sample.
internal nodes provide strong support (75-100%) for similarities or differences between
samples. The horizontal scale bar at the bottom indicates 1% sample divergence. As
shown above, there is strong support that the bacterial profile between a tissue sample
and its respective environmental control is distinct. Reads were rarified to 475
reads/sample. “E”= environmental control and “N”= tissue sample.
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4.4 Discussion
We first suggested the potential for a breast microbiome in 2012 (Urbaniak et al., 2012),
and this has now been confirmed in the present study, and recently by Xuan et al who
examined breast tumor and normal adjacent tissue also using next-generation sequencing
techniques (Xuan et al., 2014). In our study, none of the 81 women recruited had any
clinical signs or symptoms of breast infection, yet bacteria were still detected in all
Canadian samples analyzed, by both culture and molecular techniques and the Irish
samples which were analyzed by just molecular techniques. While only 8 different strains
were able to be cultured, we just used Columbia Blood Agar to isolate bacteria, and some
fastidious bacteria such as Prevotella and Bacteroides, require more nutrient rich
conditions for growth. Regardless, all those bacteria that were cultured were also detected
by 16S rRNA sequencing, supporting the argument that the DNA amplimers are from
viable bacteria and not solely from remnant bacterial DNA.
Proteobacteria was the most abundant phylum in breast tissue, unlike in the vagina, oral
cavity, bladder, skin and gastrointestinal tract where they make up only a small
proportion of the overall bacterial community (Dewhirst et al., 2010; Grice et al., 2009;
Human Microbiome Project Consortium, 2012; Hummelen et al., 2010; Wade, 2013;
Wolfe et al., 2012). This finding is similar to what was observed in Xuan et al., and
suggests that breast tissue may have a unique microbiota, distinct from that found at other
body sites, which is consistent with published studies showing that bacterial communities
vary across body habitats (Costello et al., 2009; Human Microbiome Project Consortium,
2012). The higher abundance of Proteobacteria and Firmicutes (specifically the class
Bacilli) compared with other taxonomic groups may be a result of host-microbial
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adaptation to the fatty acid environment in the tissue. A recent study documented a
positive correlation between Proteobacteria and Bacilli and the metabolic byproducts of
fatty acid metabolism, as well host derived genes involved in fatty acid biosynthesis (El
Aidy et al., 2013). It has also been documented that wild-type mice fed a high fat diet
have a gut microbiota enriched in Firmicutes (Murphy et al., 2010). Of interest,
Proteobacteria is also the principal phylum in human milk (Ward et al., 2013) with many
of the same bacteria we detected in tissue, raising the possibility that the tissue
microbiota could be a source of bacterial inocula for babies.
Some of the organisms detected in breast tissue have been found at other body sites, such
as Lactobacillus iners and Prevotella (vagina), Enterobacteriaceae (gastrointestinal
tract), Fusobacterium and Streptococcus (oral cavity), Propionibacterium and
Micrococcus (skin) and Pseudomonas (respiratory tract). Species known for their healthconferring properties, such as Lactobacillus and Bifidobacterium were detected as well as
taxa known for pathogenesis at other sites, such as Enterobacteriaceae, Pseudomonas
and Streptococcus agalactiae. We can only speculate why potentially pathogenic bacteria
do not multiply and induce infections. One concept has been proposed that it is due to a
host microbial sensory system aligned with antibacterial gene expression (Xuan et al.,
2014).
Of interest, in the Xuan study, differential abundance was observed with the genera
Sphingomonas and Methylbacterium between paired normal and tumour tissue, with the
authors suggesting a potential role in tumour development. While we also detected these
two genera in our tissue samples, further studies, with a larger sample size of healthy
women, would be needed to determine whether differential abundance between healthy
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and normal adjacent tissue also exists. While a comparison between tissue form cancer
patients and healthy women was not the focus of this paper, we did notice a higher
abundance of E.coli in women with cancer compared to healthy controls, with this
species known for its cancer promoting activity (Davis et al., 1991). However, it is
premature to suggest cause and effect until more work is done in this area.
One limitation of the study was the inability to make direct comparisons between the two
countries due to the different collection and DNA extraction techniques used. Thus no
claims can be made as to whether bacteria detected at one site differ significantly from
the other.
This research shows that breast tissue is not sterile but contains a diverse community of
bacteria, adding to the literature that body sites once believed to be sterile do indeed have
an endogenous microbiome. It has been proposed that the breast microbiome contributes
to maintenance of healthy breast tissue by stimulating resident immune cells (Xuan et al.,
2014), but the type of bacteria and their metabolic activity, such as ability to degrade
carcinogens, may also contribute. Further studies are warranted to determine how this
breast microbiome is established, why no infections accompanied colonization, what
impact these organisms have on the host and whether external factors such as diet,
antibiotics and illness affect this bacterial community and the subsequent consequences
for the woman.
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Chapter 5

5

The microbiota of breast tissue and its association with
breast cancer

This chapter is based on a manuscript under review for publication at mBio. Supporting
Datasets 5-1 (clinical metadata) and 5-2 (ALDEx2 summary) are available for download
online as additional excel files.

5.1 Introduction
Breast cancer is the leading cause of cancer death in women worldwide and it is expected
that within the next 15 years the incidence of breast cancer cases in the U.S. will increase
by 50%, resulting in 440,000 women being diagnosed by 2030 (Rosenberg et al., 2015).
The etiology of breast cancer is still unknown but is believed to be due to a combination
of genetic and environmental factors. Support for environmental factors comes from
migration studies showing increased incidence of breast cancer amongst migrants and
their descendants after they move from a region of low breast cancer risk to a region of
high risk (Le et al., 2002; Shimizu et al., 1991). While many environmental factors have
been proposed, one not yet considered is the role of the host’s local tissue microbiome in
modulating the risk of breast cancer development.
Bacteria inhabit numerous body sites and this collection of bacteria, termed the human
microbiota, plays an integral role in human development. Changes in the composition of
one’s microbiota could promote disease progression, as individuals with periodontitis
(Darveau, 2010; Ximénez-Fyvie et al., 2000), inflammatory bowel disease (Frank et al.,
2007), psoriasis (Gao et al., 2008), asthma (Hilty et al., 2010), diabetes (Larsen et al.,
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2010), bacterial vaginosis (Hummelen et al., 2010) and colorectal cancer (Mira-Pascual et
al., 2014) have different bacterial communities compared with healthy individuals. While
it is still unclear if microbiota changes are a consequence or a cause of the disease, there
is evidence in favour of the latter, as healthy animals transplanted with feaces from those
with obesity, colitis or colorectal cancer then go on to develop disease (Garrett et al.,
2007; Turnbaugh et al., 2009; Zackular et al., 2013).
The aim of the present study was to assess microbial profiles in breast tissue from women
with breast cancer and those who were disease free, and to examine the consequences of
this altered bacterial community in terms of breast cancer development. To investigate
this, we examined the breast microbiota of 71 women who had either breast cancer,
benign tumours or were disease free. Bacteria isolated from cancer patients were
characterized and examined for their ability to induce DNA damage.

5.2 Methods
5.2.1

Microbiome analysis

5.2.1.1

Tissue collection and processing

Breast tissue was collected from 71 women (aged 19 to 90) undergoing breast surgery at
St. Joseph's Hospital in London, Ontario, Canada. Ethical approval was obtained from
Western Research Ethics Board and Lawson Health Research Institute, London, Ontario,
Canada. Subjects provided written consent for sample collection and subsequent
analyses. Fifty-eight women underwent lumpectomies or mastectomies for either benign
(n=13) or cancerous (n=35) tumours, and 23 underwent either breast reductions or
enhancements and had no history of breast cancer. For those women with tumours, the
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tissue obtained for analysis was collected outside the marginal zone, approximately 5 cm
away from the tumour.
After excision, fresh tissue was immediately placed in a sterile vial on ice and
homogenized within 30 min of collection. As an environmental control, a tube filled with
1ml of sterile phosphate-buffered saline (PBS) was left open for the duration of the
surgical procedure and then processed in parallel with the tissue samples. As an added
control, a skin swab was collected of the disinfected breast area prior to surgery. The
swab was placed in 1ml of sterile PBS and then vortexed at full speed for 5min to pellet
the contents of the swab. The swab was then removed and the liquid stored at −80°C until
DNA extraction.
Tissue samples were homogenized in sterile PBS using a PolyTron 2100 homogenizer at
28,000 rpm. The amount of PBS added was based on the weight of the tissue in order to
obtain a final concentration of 0.4 g/ml. The homogenate was then stored at −80°C until
DNA extraction.

5.2.1.2

DNA isolation

After tissue homogenates, in sealed containers, were thawed on ice, 400µl (equivalent to
160 mg of tissue) was added to tubes containing 1.2 ml of ASL buffer (QIAamp DNA
stool kit; Qiagen) and 400 mg of 0.1-mm-diameter zirconium-glass beads (BioSpec
Products). 800µl of the PBS control and 800µl of the skin swab control was also added to
tubes containing ASL buffer and beads. Mechanical and chemical lyses were performed
on all samples by bead beating at 4,800 rpm for 60s at room temperature and then 60s on
ice (repeated twice) (Mini-Beadbeater-1; BioSpec Products), after which the suspension
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was incubated at 95°C for 5 min. Subsequent procedures were performed using the
Qiagen QIAamp DNA stool kit according to the manufacturer's protocol, with the
exception of the last step, in which the column was eluted with 120µl of elution buffer.
DNA was stored at −20°C until further use.

5.2.1.3

PCR amplification

The genomic DNA isolated from the clinical samples was amplified using barcoded
primers that amplify the V6 hypervariable region of the 16S rRNA gene:
V6-Forward:
5’ACACTCTTTCCCTACACGACGCTCTTCCGATCTnnnn(8)CWACGCGARGAACC
TTACC 3’
V6-Reverse:
5’CGGTCTCGGCATTCCTGCTGAACCGCTCTTCCGATCTnnnn(8)ACRACACGAGCT
GACGAC 3’

nnnn indicates 4 randomly incorporated nucleotides and “8” represents a specific sample
barcode sequence. The PCR was carried out in a 42µl reaction containing 2µl of DNA
template (or nuclease-free water as a negative control), 0.15 µg/µl bovine serum albumin,
20µl of 2x GoTaq hot start colorless master mix (Promega) and 10µl of each primer
(initial concentration: 3.2pmol/µl). Thermal cycling was carried out in an Eppendorf
Mastercyler under the following conditions: initial denaturation at 95°C for 2 minutes
followed by 25 cycles of 95°C for 1 minute, 55°C for 1 minute and 72°C for 1 minute.
After amplification, the DNA concentration was measured with the Qubit® 2.0
Fluorometer (Invitrogen) using the broad range assay. Equimolar amounts of each PCR
product were then pooled together and purified using the QIAquick PCR purification kit
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(QIAGEN). The pooled PCR purified sample was then paired-end sequenced on the
Illumina Mi-Seq platform using a 150 cycle kit with a 2x80 run at the London Regional
Genomics Center, London, Ontario, Canada following standard operating procedures.

5.2.1.4

Sequence processing and taxonomic assignment

Custom Perl and Bash scripts were used to de-multiplex the reads and assign barcoded
reads to individual samples. Multiple layers of filtering were employed: (i) Paired end
sequences were overlapped with Pandaseq, allowing 0 mismatches in the overlapped
reads; (ii) Reads were kept if the sequence included a perfect match to the V6 16S rRNA
gene primers; (iii) Barcodes were 8mers with an edit distance of >4 and reads were kept
if the sequence were a perfect match to the barcode; (iv) Reads were clustered by 97%
identity into operational taxonomic units (OTUs) using the Uclust algorithm of
USEARCH v7 (Edgar, 2010) which has a de novo chimera filter built into it; (v) All
singleton OTUs were discarded and those that represented ≥2% of the reads in at least
one sample were kept (a filter for PCR and environmental controls and the skin swabs).
Taxonomic assignments for each OTU were made by extracting the best hits from the
SILVA database (Pruesse et al., 2007) and then manually verified using the Ribosomal
Database Project (RDP) SeqMatch tool (rdp.cme.msu.edu) and by BLAST against the
Green genes database (greengenes.lbl.gov) Taxonomy was assigned based on hits with
the highest percentage identities and coverage. If multiple hits fulfilled this criterion,
classification was re-assigned to a higher common taxonomy.

5.2.1.5

Data analysis

PCoA plots of weighted UniFrac distances (Lozupone and Knight, 2005) were generated
in QIIME (Caporaso et al., 2010) by using a tree of OTU sequences built with
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FASTTREE (Price et al., 2009) based on an OTU sequence alignment made with
MUSCLE (Edgar, 2004). PERMANOVA was used to test for statistical significance
between groups using 10000 permutations (QIIME package).
Microbiome data is compositional in nature (i.e. proportional distributions that are not
independent of each other) and thus has several limitations (Fernandes et al., 2014). A
simple example is as follows: If a sample has two organisms A (50%) and B (50%) and
after antibiotic treatment organism A is completely killed, the proportion of B in that
sample will now be 100% even if its actual abundance has not changed. Transforming
the data, using centered log-ratios (CLR) alleviates the constraints inherent with
compositional data (Aitchison, 1986) by allowing for subcomposition coherence, linear
sample independence and normalization of read counts. CLR transformed data with a
uniform prior of 0.5 applied was used when generating the K-means clusterplot and the
dendogram of Euclidian distances.
The ALDEx R package version 2 (Fernandes et al., 2014) was used to compare genera
the relative abundance of genera. Values reported in this manuscript represent the
expected values of 128 Dirichlet Monte-Carlo instances of CLR transformed data. A
value of zero indicates that organism abundance is equal to the geometric mean
abundance. Thus, organisms more abundant than the mean will have positive values and
those less abundant than the mean will have negative values. Base 2 was used for the
logarithm so differences between values represent fold changes. Significance was based
on the Benjamini-Hochberg corrected p-value of the Wilcoxon rank test (significance
threshold of 0.1).
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The Microbiome Regression-based Kernel Association Test (MiRKAT) (Zhao et al.,
2015) was performed in R using the MiRKAT package. Differences in microbiota
profiles were tested using a kernel metric constructed from weighted UniFrac,
unweighted UniFrac and GUniFrac (Chen et al., 2012) distances and the Bray-Curtis
dissimilarity metric. “Optimal” MiRKAT allows for the simultaneous examination of
multiple distance/dissimilarity metrics alleviating the problem of choosing the best one
and was performed on the aforementioned metrics. The p-values generated were the
mean of 128 Dirichlet Monte-Carlo instances.
The R script of “SourceTracker “(version 0.9.1) was used to assess contamination of the
tissue microbiota. Tissue samples were designated as “sink” and PBS controls as
“source.” Barplots, boxplots, K-means clusterplots and dendograms were all generated in
R (http://www.R-project.org/).
Full details regarding Irish tissue sample collection, patient demographics, DNA
extraction protocols and the steps followed to generate the OTU table used for the
analysis in Figure 5-6, can be found in our previous publications (Lehouritis et al., 2015;
Urbaniak et al., 2014).

5.2.2

DNA damage assay

5.2.2.1

Bacterial strains

Isolates were obtained by plating 100µl of tissue homogenate on Columbia blood (CBA),
MacConkey and Beef Heart Infusion (BHI) agar plates and incubating both aerobically or
anaerobically at 37oC. DNA from single colonies was extracted using the InstaGene
Matrix (Bio-Rad) and then amplified using the eubacterial primers pA/pH, which
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amplifies the complete 16S rRNA gene (see section 4.2.4 for the primer sequences). The
PCR reaction was carried out in 50µl reaction containing 10µl of DNA template (or
nuclease free water as a negative control), 1.5mM MgCl2, 1.0µM of each primer, 0.2mM
dNTP, 5µl 10X PCR buffer (Invitrogen), and 0.05 Taq Polymerase (Invitrogen). Thermal
cycling was carried out in an Eppendorf Mastercyler under the following conditions:
Initial denaturation step at 95oC for 2min, followed by 30 cycles of 94oC for 30s, 55oC
for 30s and 72oC for 1min. A final elongation step was performed at 72oC for 10min.
40µl of the PCR mixture was then purified using the QIAquick PCR purification kit
(Qiagen) and the purified products sent for Sanger sequencing to the London Regional
Genomics Centre, London, Ontario, Canada. Sequences were analyzed using the
GenBank 16S ribosomal RNA sequences database and the Greengenes database.
Taxonomy was assigned based on the highest Max score. Because the 16S rRNA gene
does not differentiate members of the Enterobacteriaceae family very well, to confirm
that our isolates were indeed E.coli, we utilized the API

®

20E strip to differentiate

species that are part of the this family. E.coli strain IHE3034 was kindly provided by Jean
Philippe Nougayrède (INRA, Toulouse, France).

5.2.2.2

Infection assay

HeLa cells were maintained and passaged in DMEM/glutamax media (Invitrogen)
supplemented with 10% FBS (Invitrogen). On the day of the experiment a 24 well plate
containing sterile cover slips was seeded with 0.5ml of 1x105 cells/ml, resulting in 5x104
HeLa cells/well. The plates were then incubated at 37oC with 5% CO2 for 24 hours after
which times the media was removed and the wells washed with sterile PBS. HeLa cells (2
wells for each organism) were then infected at a MOI 100 cfu of bacterial cells per HeLa
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cell for 4 hours with either Staphylococcus epidermidis (subject 31), Micrococcus luteus
(subject 8), Micrococcus sp (subject 8), E.coli (subject 41 (isolates H and E), subject 34
and strain IHE3034), Propionibacterium acnes (subject 20) and P. granulosum (subject
20) or at a MOI 1 for 2 hours with Bacillus cereus (subject 34 & subject 6). The bacterial
cultures for infection were prepared by inoculating 5ml of BHI with 1 colony and
incubating aerobically at 37oC for 15 hours, with the exception of Propionibacterium,
which was incubated anaerobically for 72hr. Bacterial cultures were then spun down at
3500g for 10min, washed and resuspended in PBS. Bacterial cells were then diluted to
the appropriate concentration in DMEM media containing 10% FBS and 25mM HEPES.
40µM etoposide (Sigma) was used as a technical positive control. The pH was checked at
the end of the experiment to ensure consistency between wells.

5.2.2.3

Immunofluorescence

After infection, media was removed and HeLa cells were washed 3x with sterile PBS.
Cells were then fixed and permeabilized for 12min at room temperature (RT) with a
-20oC solution of 95% methanol and 5% acetic acid. Cells were then blocked for an hour
with 0.3% Triton-100/5% goat serum. After blocking, a 1/200 dilution of the primary
antibody (rabbit anti phospho-H2AX mAb; Cell Signaling technologies) was added and
incubated over night at 4oC. After washing a 1/1000 dilution of the secondary antibody
(goat anti-rabbit IgG, Alexa Fluor 647 conjugate; Cell Signaling technologies) was added
and incubated at RT for 30min. Cells were then counter stained with 1µg/ml of DAPI
(Life Technologies) for 1min. Cover slips were mounted on microscope slides containing
a drop of ProLong Gold antifade mountant (Life Technologies). The experiments were
performed three times.
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Images were captured using the NIKON eclipse TE2000-S digital microscope. Eight
fields of view for each replicate were recorded, for a total of 16 fields of view for each
condition. Using ImageJ software (version 1.48a), the mean fluorescent intensity of each
γH2AX stained cell was measured from the digital images. The digital images were also
used to determine the percent of total cells stained positive for γH2AX, which was
calculated by dividing the number of red cells (i.e. γH2AX positive) by the number of
blue cells (i.e. DAPI stained) and multiplying by one hundred.

5.2.2.4

Statistics

Bar graphs of the mean and standard deviation from the 3 experiments were plotted using
Prism (version 5.0a). Significance (p<0.05) was tested by a 1 way ANOVA followed by
a 2-sided unpaired student’s t-test (Prism v 5.0a) with the false discovery rate (“FDR”)
multiple test correction performed in R.

5.3 Results
5.3.1

Microbiota analysis

16S rRNA amplicon sequencing of the V6 hypervariable region was performed on 70
tissue samples and 38 environmental controls. A full summary of patient demographics
can be found in Dataset 5-1. To assess the contribution of environmental contamination
towards the overall tissue microbiota, we utilized the contamination predictor tool,
“SourceTracker”, which compared the microbial population in the tissue samples to that
of the phosphate buffered saline (PBS) environmental controls. Figure 5-1 shows that
while there is contamination present, it makes up only a small proportion (average 10%)
of the overall microbial community in breast tissue. A dendogram of Euclidian distances
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of the centered log-ratio (clr) transformed dataset (Aitchison, 1986) was then constructed
to visualize which tissue samples were similar to the PBS controls and to skin swabs
collected from the disinfected breast area prior to surgery. As seen in Figure 5-2, skin
swabs, PBS controls and the no template PCR control (NTC) formed a single cluster,
which was separate from most of the tissue samples, indicating distinct microbial
profiles. It is also important to note that no differences were observed within the controls
and within tissue samples obtained from different surgeons and surgical rooms. To ensure
stringent quality control, we removed those tissue samples that were part of the
PBS/skin/NTC cluster from further analysis. In addition, OTUs present in over 2%
abundance in the NTC and PBS controls were also removed from further analysis. 16S
rRNA sequencing data of the remaining samples and OTUs, showed a diverse population
of bacteria consisting of 61 OTUs and 28 taxa (Figure 5-3A) dominated by the phyla
Proteobacteria and Firmicutes (Figure 5-3B).
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Figure 5-1. Assessment of DNA contamination towards the breast tissue microbiota
SourceTracker was used to examine if and in what proportion the tissue microbiota was
contaminated with environmental DNA by comparing the OTUs detected in the PBS
environmental controls to that of the OTUs detected in breast tissue. While there is some
contamination present, as would be expected in low biomass samples, this contamination
Sample BTS2

Sample BTS12

Sample BTS22

makes up only 10% of the overall bacterial community in tissue. Each pie graph
corresponds to one subject. The pink slices represent the proportion of OTUs in the tissue
samples that are similar to those found in the PBS controls. The blue slices represent the
OTUs unique to the tissue samples.
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Figure 5-2. Examining the relatedness of bacterial profiles in tissue samples to that
of the environmental controls
Dendogram of Euclidian distances were constructed from centered log-ratio transformed
data to compare bacterial profiles between tissue samples, PBS controls, skin swabs and
the no template PCR control. Two distinct branches are evident, separated by a red line.
One branch consists of tissue samples (right of red line) and the other mainly of
environmental controls (left of the red line). Those samples that fell within the
environmental control branch (left) were removed from further analysis. “HC”- PBS
control during surgery of healthy patients; “BTC”= PBS control during surgery of tumour
patients; neg= PCR no template control; skin= skin swab of either healthy patients (“H)
or tumour patients (“BT”)

132

Figure 5-3.

Breast tissue microbiota identified by 16S rRNA gene amplicon

sequencing.
(A) The relative abundances of bacterial genera in different breast tissue samples were
visualized by bar plots. Each bar represents a subject and each colored box a bacterial
taxon. The height of a coloured box represents the relative abundance of that organism
within the sample. Taxa present in less than 2% abundance in a given sample are
displayed in the “Remaining fraction” at the top of the graph (gray boxes). As shown by
the bar plots, a variety of bacteria were detected in breast tissue. The legend is read from
bottom to top, with the bottom organism on the legend corresponding to the bottom
colored box on the bar plot. (B) Box plots of the six phyla identified in breast tissue. The
box signifies the 75% (upper) and 25% (lower) quartiles and thus shows where 50% of
the samples lie. The black line inside the box represents the median. The whiskers
represent the lowest datum still within 1.5 interquartile range (IQR) of the lower quartile
and the highest datum still within 1.5 IQR of the upper quartile. Outliers are shown with
open circles
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A comparison of normal adjacent tissue from women with breast cancer with that of
tissue from healthy women showed distinctly different bacterial profiles on weighted
UniFrac PCoA plots (Figure 5-4A). Unsupervised K-means clustering of the clr
transformed dataset indicated two clusters and the PCA plot in Figure 5-4B shows clear
separation between the healthy and cancer groups. Differences between the groups were
also confirmed using the Microbiome Regression-based Kernel Association Test
(MiRKAT) (Table 5-1).

Table 5-1. Summary of p-values generated by MIRKAT
p-values displayed represent the min, max, average and median values generated from
128 Dirichlet Monte-Carlo instances
Bray-Curtis

Weighted
UniFrac
Min
4.58E-05
2.64E-06
Max
0.000129826 1.04E-05
Average 7.87E-05
4.52E-06
Median 7.70E-05
4.24E-06

Unweighted
UniFrac
4.12E-06
0.004191322
0.000395004
2.05E-04

GUniFrac
α=0.5
2.64E-06
1.15E-05
5.33E-06
4.87E-06

Optimal
0
0
0
0

ALDEx2, which allows for the direct comparison of bacterial taxa between groups
showed significantly higher compositional abundances of Prevotella, Lactococcus,
Streptococcus Corynebacterium and Micrococcus in healthy patients and Bacillus,
Staphylococcus, Enterobacteriaceae (unclassified), Comamondaceae (unclassified) and
Bacteroidetes (unclassified) in cancer patients (Figure 5-5)(Dataset 5-2).
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Figure 5-4. Comparison of bacterial profiles between breast cancer patients and
healthy controls
(A) Weighted UniFrac principal coordinate (PCoA) plot and (B) K-means clusterplot of
centered log-ratio transformed data. Each breast tissue sample, represented by a coloured
point is plotted on a three-dimensional, 3-axis plane representing 79% of the variation
observed between all samples (A) or 44.85% of the variation on a 2-axis plane (B).
Samples (points) that cluster together are similar in biota composition and abundance.
The distinct separation between the two groups indicates that bacterial profiles differ
between women with and without cancer. The PERMANOVA test performed on the
weighted UniFrac distances showed that the observed differences were statistically
significant (10000 permutations; pseudo F-statistic=14.4; p-value <0.01).
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Figure 5-5. Differences in relative abundances of taxa exist between healthy and
cancer patients
Summary of taxa that were statistically significantly different between the two groups as
determined by ALDEx2. The top panel shows the bacteria that were higher in healthy
patients compared to those with cancer (i.e. normal adjacent tissue) and the bottom panel
shows the bacteria that were higher in cancer patients compared to healthy controls. The
box signifies the 75% (upper) and 25% (lower) quartiles and thus shows where 50% of
the samples lie. The black line inside the box represents the median. The whiskers
represent the lowest datum still within 1.5 interquartile range (IQR) of the lower quartile
and the highest datum still within 1.5 IQR of the upper quartile. Outliers are shown with
open circles.
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To assess whether bacteria surrounding the tumour microenvironment might be
associated with the severity of cancer, we compared bacterial profiles in normal adjacent
tissue from women with various stages of breast cancer. No differences were found based
on invasiveness or stage (data not shown). However normal adjacent tissue from women
with benign tumours had profiles that were more similar to normal adjacent tissue of
women with cancerous tumours rather than tissue from healthy subjects (Table 5-2).

Table 5-2. Comparison of relative abundances of bacteria in breast tissue between
women with benign tumours, cancerous tumours and healthy controls.
ALDEx2 was performed to compare the relative abundances of bacteria in breast tissue
between healthy women, and normal adjacent tissue from those with benign tumours and
cancerous tumours. Bacterial profiles in normal adjacent tissue from women with benign
tumours are more similar to normal adjacent tissue from women with cancerous tumours
rather than healthy controls.
Cancer vs Healthy
Higher in Healthy
Prevotella
Lactococcus
Corynebacterium
Streptococcus
Micrococcus

Benign vs Healthy
Higher in Healthy
Prevotella
Lactococcus

Higher in Cancer
Bacillus
Staphylococcus
Enterobacteriaceae
Comamonadaceae
Bacteroidetes unclassified

Higher in Benign
Bacillus
Staphylococcus

Benign vs Cancer
Higher in Benign
Micrococcus
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We have previously published two reports showing which bacteria are present in tumour
tissue and normal adjacent tissue of women from Ireland (Lehouritis et al., 2015;
Urbaniak et al., 2014). In this report, we now show, using weighted UniFrac distances,
that bacterial communities do not differ between tumour tissue and normal adjacent
tissue, both at the population level (Figure 5-6A) and within an individual (Figure 56B). Thus, when suitably-collected tumour tissue for microbiome analysis is not
available, normal adjacent tissue may be a practical alternative.
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Figure 5-6. Comparison of bacterial profiles between tumour tissue and normal
adjacent tissue
Tissue from malignant tumours and matched normal adjacent (i.e. non-malignant) tissue
from 33 women from Cork, Ireland were collected and analyzed. (A) Weighted UniFrac
PCoA plots to assess bacterial profiles at the population level. Lack of distinct clustering
between tumour and normal adjacent tissue groups indicates that bacterial profiles are
similar between the two tissue types. (B) Differences in microbial communities between
conditions can sometimes exist within an individual, which may not be evident at the
population level. To examine whether this was the case, weighted UniFrac distances were
analyzed between matched tumour and normal adjacent tissue (i.e. “paired”). The smaller
the weighted UniFrac distance is between two samples, the more related they are. As
depicted in the boxplots, the UniFrac distances between paired samples was even smaller
than the distances calculated between all normal adjacent tissue (NA vs NA), all tumour
tissue (T vs T) and between normal adjacent and tumour tissue (NA vs T) showing that
even within an individual bacterial profiles are the same between tumour and normal
adjacent tissue. ** denotes p-value <0.01 (1- way ANOVA, followed by a student’s ttest with the FDR multiple test correction).

141

Figure%S3%
A%
red=%normal%adjacent%
blue0=tumour%

**""p<0.01%
1.0
0.8
0.6
0.4
0.2

N

A

A
N

T

vs

vs

T

A
N
vs

T

0.0

Pa
ire
d

Weighted UniFrac distance

B%

Samples

142

5.3.2

Assessment of DNA damage ability of breast tissue
isolates

E.coli strains belonging to the B2 phylotype harbour the pks pathogenicity island, which
encodes for machinery for the production of the genotoxin, colibactin. These pks + strains
have been implicated in colon cancer (Arthur et al., 2012; Buc et al., 2013) via their
ability to induce DNA double stranded breaks and chromosomal instability (CuevasRamos et al., 2010; Nougayrède et al., 2006). As shown in Figure 5-5, the family
Enterobacteriaceae, of which E.coli is a member of, was relatively more abundant in
cancer patients compared to healthy controls. For this reason, we wanted to examine
whether E. coli, cultured from breast tissue of cancer patients, had the ability to induce
DNA double stranded breaks (DSB). Cellular levels of γH2AX, a surrogate marker of
DSB, were measured in HeLa cells after incubation with various E.coli tissue isolates.
E.coli IHE3034, which contains the pks pathogenicity island and induces DSB
(Nougayrède et al., 2006) was used for comparison.
HeLa cells exposed to E.coli tissue isolates had significantly higher levels of γH2AX
compared with untreated cells, as measured by mean fluorescent intensity (MFI) and %
of cells that stained positive for γH2AX, with levels equivalent to that induced by E.coli
IHE3034 (Figure 5-7). Additional isolates from breast cancer patients were also
examined for the ability to induce DNA damage; (i) Bacillus and Staphylococcus were
tested as these genera were more abundant in cancer patients; (ii) Micrococcus, as this
genus was higher in healthy individuals and (iii) Propionibacterium as there were no
differences in relative abundances between cancer patients and healthy controls. Neither
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Bacillus, Microccoccus nor Propionibacterium isolates induced DSB, whereas
Staphylococcus did (Figure 5-8).
γH2AX foci can occur and be resolved very quickly in response to DNA damage, thus a
time course was performed, with Bacillus treated cells analyzed every 15min over a 2
hour period. No statistically significant differences at any time point were observed
between treated and untreated cells (data not shown).
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Figure 5-7. DNA damage ability of E.coli breast tissue isolates from cancer patients.
E.coli was isolated from normal adjacent tissue of 2 patients with breast cancer and tested
for its ability to induce DNA double stranded breaks. E.coli (isolates H and E) from
subject 41, isolate L from subject 34 and strain IHE3034 were incubated with HeLa cells
at MOI 100 cfu bacteria per HeLa cell for 4hr and then stained for γH2AX and DAPI. (A)
Representative immunofluorescent images of HeLa cells at 1000x magnification. (B)
Image J was used to measure the mean fluorescent intensity (MFI) of γH2AX positive
cells from the digitally acquired images. (C) Percent of total cells stained for γH2AX
calculated from the immunofluorescent images.

Data displayed in the bar graphs

represent the mean +/- SD of 3 experiments representing a total of 48 fields of view and
approximately 300 cells for each treatment group. ** denotes p-value <0.01
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Figure 5-8. DNA damage ability of bacteria isolated from breast tissue of cancer
patients
Bacteria isolated from normal adjacent tissue of patients with breast cancer were tested
for their ability to induce DNA double stranded breaks. Staphylococcus epidermidis,
Micrococcus luteus, Micrococcus sp, Propionibacterium acnes and Propionibacterium
granulosum were incubated with HeLa cells at MOI 100 cfu bacteria per HeLa cell for
4hr or with Bacillus cereus at MOI 1 for 2hr and then stained for γH2AX and DAPI. (A)
Image J was used to measure the mean fluorescent intensity (MFI) of γH2AX positive
cells from digitally acquired immunofluorescent images. (B) Percent of total cells stained
for γH2AX calculated from the immunofluorescent images. Data displayed in the bar
graphs represent the mean +/- SD of 3 experiments (with the exception of
Propionibacterium which was only done once) representing a total of 48 fields of view
and approximately 300 cells for each treatment group. * denotes p-value <0.05.
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5.4 Discussion
This study has shown that different bacterial profiles exist in “normal adjacent” breast
tissue from women with breast cancer compared with “normal” tissue from healthy
controls. In colorectal cancer (CRC) and oral squamous cell carcinoma (OSCC) bacterial
profiles in the stool and saliva respectively, also differ between healthy and diseased
patients (Mager et al., 2005; Wang et al., 2012; Weir et al., 2013) with evidence
suggesting that changes in this community composition and function may be driving
cancer progression at these sites (Ahn et al., 2012; Schwabe and Jobin, 2013). This raises
the possibility that the differences observed in the breast could also play a role in breast
cancer progression.
Enterobacteriaceae and Staphylococcus are two taxa found in higher abundance in breast
cancer patients compared with healthy controls. Examination of three E.coli isolates (a
member of the Enterobacteriaceae family) and one Staphylococcus epidermidis isolate,
cultured from normal adjacent tissue of breast cancer patients, all displayed the ability to
induce DNA double stranded breaks (DSB). DSB are the most detrimental type of DNA
damage and are caused by genotoxins, reactive oxygen species, and ionizing radiation
(Lees-Miller, 2003). Non-homologous end joining, the mechanism by which DSB are
repaired, is extremely error- prone often resulting in missing bases at the site of damage
(Lees-Miller, 2003). Accumulation of these mis-repairs within the cell over time leads to
genomic instability and eventually cancer (Khanna and Jackson, 2001). DSB caused by
bacteria such as Helicobacter pylori and certain strains of E.coli have been shown to
induce chromosomal instability with prolonged exposure (Cuevas-Ramos et al., 2010;
Toller et al., 2011). While the same mechanisms may be involved in the in vitro assay
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described here (or indeed breast tissue transformation), further tests would need to be
done to verify whether chromosomal abnormalities do occur subsequent to the DNA
damage induced by these breast isolates. In support of this hypothesis, total cell numbers
were consistent between all treated and untreated groups, suggesting no induction of
apoptosis. It is important to note that bacterial induced DNA damage may not be
sufficient in itself to promote breast cancer development unless it occurs in a genetically
susceptible host. All genetic and 3-30% of sporadic cancer cases have mutations in DNA
repair or DNA checkpoint machinery (Negrini et al., 2010). Thus women who have
impaired DNA repair/checkpoints may be more susceptible to bacterial induced DNA
damage and may be at a higher risk of developing breast cancer than women without
these mutations, even if they have the same “detrimental” microbes in their mammary
glands.
Bacillus was also elevated in breast cancer patients compared with healthy controls,
confirming our previous findings (Urbaniak et al., 2014). While Bacillus did not induce
DSB like E.coli and S.epidermidis it could have other pro-carcinogenic effects. One study
has shown that a Bacillus cereus strain, isolated from gingival plaque, metabolizes the
hormone progesterone into 5 alpha-pregnane-3,20-dione (5αP) (Ojanotko-Harri et al.,
1990). 5αP is higher in breast tumours compared with healthy breast tissue (Wiebe et al.,
2000) and is believed to promote tumour development by stimulating cell proliferation
(Wiebe, 2006; Wiebe et al., 2000). While our molecular analysis did not permit species
level identification, all Bacillus strains cultured from our breast cancer patients were of
the species B.cereus.

150

An epidemiological study has shown that women who drink fermented milk products
have a reduced risk of breast cancer development, irrespective of multivariable risk
factors (van’t Veer et al., 1989). This protection could be attributed to the health
promoting properties of the various lactic acid bacteria (LAB) present in fermented
products. Lactococccus and Streptococcus, two such bacteria that were higher in healthy
women compared with breast cancer patients, exhibit anti-carcinogenic properties and
could play a role in prevention. Natural killer (NK) cells are vital in controlling tumour
growth with epidemiological studies showing that low NK cell activity from PBMC is
associated with an increased incidence of breast cancer (Imai et al., 2000; Strayer et al.,
1984). Lactococcus lactis has been shown to activate murine splenic NK cells, enhancing
cellular immunity (Kosaka et al., 2012). While no studies have yet been published
comparing NK cell functionality in the breast between “normal” (i.e. healthy patients)
and “normal adjacent” (breast cancer patients) tissue, it could be assumed, based on the
PBMC data, that NK functionality is also impaired in the breast of those with cancer.
Lactococcus sp present in the mammary glands, could be modulating cellular immunity
by maintaining the cytotoxic activity of resident NK cells (Carrega et al., 2014) thus
helping to prevent cancer development. Streptococcus thermophilus on the other hand,
better than any other LAB tested, protects against DNA damage caused by reactive
oxygen species by producing antioxidant metabolites that neutralize peroxide and
superoxide radicals (Koller et al., 2008).
Orally administered Lactobacillus sp, has shown to be protective in animal models of
breast cancer (de Moreno de LeBlanc et al., 2005). While total numbers did not differ
between healthy and diseased patients, those with breast cancer may not experience the
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full anti-carcinogenic benefits afforded by Lactobacillus due to the decrease in
Lactococcus and Streptococcus, as LAB have been shown to act in synergy with each
other (Shiou et al., 2013).
Prevotella, which was more abundant in healthy women compared with breast cancer
patients, produces the short chain fatty acid (SCFA), propionate. Propionate, like other
SCFA, has many beneficial health effects in the gut, one of them being the ability to
regulate colorectal tumour growth (Hosseini et al., 2011). In both animal and human
studies, higher levels of Prevotella were observed in the stool of healthy subjects
compared to those with CRC (Weir et al., 2013; Zackular et al., 2013). However in the
oral cavity, patients with OSCC have higher levels of Prevotella compared with healthy
controls and when Prevotella presence was used as a diagnostic tool, the authors could
predict 80% of the cancer cases (Mager et al., 2005). The conflicting association of
Prevotella in CRC and OSCC could be due to the fact that metabolites function
differently at different body sites. While SCFA are anti-inflammatory in the colon and
associated with health (Louis et al., 2014), in the vagina, they are pro-inflammatory and
associated with bacterial vaginosis (Aldunate et al., 2015). What role Prevotella and/or
propionate may be playing in breast health (or disease) remains to be determined.
While we have reported differential abundances of certain organisms between health and
diseased states, in reality, it is probably not a single organism driving disease progression
or protection but rather an interplay of poly-microbial interactions. To get a better
understanding of the microbial influence on breast cancer, the functionality of these
microbes should be investigated. Further studies examining bacterial metabolites and
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bacterial-induced host metabolites would provide vital information on the role of bacteria
in breast health.

5.5 Conclusion
This is the first report, to our knowledge to show that bacterial profiles differ in breast
tissue between healthy subjects and normal adjacent tissue of breast cancer patients.
Some of the bacteria that were relatively more abundant in breast cancer patients had the
ability to induce DNA double stranded breaks. Further studies need to be done to
examine whether this DNA damage can lead to chromosomal aberrations and whether the
differences in the bacterial profiles are a cause or a consequence of the disease. This
study raises important questions as to the role of the breast microbiota in breast cancer
development or prevention and whether bacteria could be harnessed for interventions to
help prevent disease onset.
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Chapter 6

6

Draft genome sequence of a Bacillus cereus strain
isolated from non-malignant breast tissue from a
woman with breast cancer

6.1 Genome announcement
Bacillus cereus was the predominant organism cultured from the breast of cancer patients
that we studied (normal adjacent tissue), with it being present in more than half of the
samples tested. No isolates were cultured from healthy controls (women undergoing
breast reductions or enhancements). 16S rRNA gene targeted sequencing of the V6
hypervariable region showed higher relative abundances of Bacillus sp in breast cancer
patients compared to healthy controls (Chapter 5). Previously, B. cereus, isolated from
gingival pockets of a patient with periodontitis, has shown the ability to metabolize
progesterone into metabolites that increase the risk of breast cancer development
(Ojanotko-Harri et al., 1990; Wiebe, 2006). Various species of Bacillus (though not B.
cereus) are dominant in pulmonary tissue from lung cancer patients (Apostolou et al.,
2011). To get a better understanding of what B. cereus could be doing in the breast and
whether it could have a role in breast cancer development or progression, we sequenced
the genome of a B. cereus isolate, designated CU-1, cultured from a 70 year- old woman
with stage 1 invasive breast cancer.
Genomic DNA was isolated using the PureLink Genomic DNA Mini Kit (Invitrogen).
Libraries were then made using the Nextera XT DNA Library Preparation Kit (Illumina)
and paired end sequenced (2x150bp) on the Illumina MiSeq platform (London Regional
Genomic Center, London, Canada). Reads were assembled into contigs using Velvet
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(version 1.2.10) set at the optimal kmer size of 31. 1467 contigs >100bp were generated,
with 17x read coverage within contigs and an N50 of 17818bp. Gene calling of the
assembled genome was carried out with RAST. A genome comparison between our
breast tissue isolate and other fully sequenced B. cereus genomes, deposited in NCBI,
was performed using JSpecies (version 1.2.1), an in silico alternative to DNA-DNA
hybridization.
The B. cereus CU-1 strain has a genome size of 5.5 Mb, typical of other B. cereus strains.
RAST analysis revealed 5536 coding sequences, with 41% assigned to a functional
subsystem (Figure 6-1).

Figure 6-1. Schematic of protein functional groups
5536 coding sequences of B. cereus CU-1 were annotated with RAST and assigned to
different functional groups (i.e. “subsystems’). Of the 5536 coding sequences, 41%
belonged to a subsystem.
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JSpecies comparisons showed that CU-1 was similar to other B.cereus strains, being the
most similar to B.cereus ATCC14579 (Table 6-1). Interestingly, our strain and not any of
the others in Table 6-1, has the Lde efflux pump, which is associated with
fluoroquinolone resistance. Since fluoroquinolones are synthetic antibiotics, this lends
weight to the idea of CU-1 being associated with the human body over a period of time.

Table 6-1. JSpecies analysis comparing B. cereus CU-1 to other B. cereus isolates
with fully sequenced genomes.
A comparison was also performed with a different species from the same genera. The
tetra regression coefficient is an indication of how similar two strains are, with values
closer to “1” representing more similarity
Name
B.cereus ATCC14579
B.cereus B4264

Tetra regression
0.99934
0.99908

B.cereus F837/76
B.cereus ATCC10987
B.cereus 03BB102

0.99845
0.99844
0.99841

B.cereus E33L

0.9984

B.cereus NC7401

0.99834

B.subtilis subspecies
subtilis str.168

0.72452

Description
Avirulent strain type strain
Isolated from male patient with fatal
pneumonia
Isolated from prostate wound
Dairy isolate, avirulent strain
Isolated from blood from a male welder
with fatal pneumonia
Isolated from a swab of a zebra carcass
in Namibia
Produces high levels of the emetic toxin
cereulide, isolated from symptomatic
patient
Strain 168 was isolated after B. subtilis
Marburg was mutagenized with X-rays
by two Yale University botanists.
Nearly all B.subtilis strains used in
academia are derivatives of strain 168.
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The genome was examined for genes involved in estrogen or progesterone metabolism,
as hormone regulation plays a key role in many types of breast cancer. However none of
these were present in our strain. Other genes were identified that could play a role in
breast cancer development or prevention (Table 6-2) but future in vitro studies would
need to confirm their functionality.
Overall, although the fully closed genome of CU-1 was not mapped, the analysis shows a
genome with the genetic tools for virulence and regulation of cancer development. The
well known pathogenicity of this species and the lack of obvious infection in this patient
raises an interesting question regarding the activity of CU-1 within the breast and a
possible role of the breast tissue environment in down regulating or inhibiting the
expression of these virulence genes.

162

Table 6-2. Potential proteins involved in cancer development or protection.
Analysis of the 5536 coding sequences revealed proteins that could contribute to health
and disease. The ones with a possible connection with breast cancer progression or
prevention are shown in this table
Protein
Toxins: Hemolysin BL, Non- hemolytic
enterotoxin, Cytotoxin K
Chitin binding protein and chitinase

Azurin

Bacillolysin

S layer

Description
Known to cause disease in humans. Have
the potential to induce DNA damage
Chitin is the second most abundant
polysaccharide in nature next to cellulose.
Chitinases are found in a variety of
prokaryotes even though they do no
produce endogenous chitin. It is believed
that chitin binding protein and chitinases
act as virulence factors in some pathogens
by modulating adhesion and/or invasion
into host cells. Increased serum levels of
chitinase correlate with disease severity,
poorer prognosis, and shorter survival in
many human cancers such as breast, colon,
prostate, ovaries, brain, thyroid, lung, and
liver.
Azurin released from Pseudomonas
aeruginosa blocks breast cancer cell
proliferation and induces apoptosis through
the mitochondrial pathway both in vitro
and in vivo. Azurin is being considered as a
potential chemotherapeutic treatment for
breast cancer.
Bacillolysin is an enzyme found in many
Bacillus species. It has been shown that
bacillolysin from B. megaterium has the
ability to convert plasminogen to
angiostatin-like fragments. Angiostatin
inhibits proliferation of vascular
endothelial cells, which is a fundamental
process in angiogenesis. Angiostatin has
been shown to suppress both in situ and
metastatic tumour growth in animal
models.
S-layers from Bacillaceae function as
adhesion sites for cell associated exoenzymes. Strains containing S-layers are
resistant to polymorphonulcear leukocytes
in the absence of opsonins.
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Chapter 7

7

Discussion

7.1 Verification of a breast tissue microbiome
The tissue microbiota data presented in Chapters 4 and 5 challenge the assumption that
breast tissue is sterile unless under active infection. While HTS has allowed scientists to
unravel the diversity and functionality of microbial communities across the body,
concerns have been raised that sites once thought of as sterile but now purported to have
a “microbiome” are really just contaminated DNA, sequenced from reagents and
laboratory equipment (Salter et al., 2014). I dispute this suggestion for the work reported
herein. In these studies, numerous aliquots of PBS (“environmental” controls) were
processed in parallel with the tissue samples. Most of the tissue samples had microbial
profiles that were different from the controls. Those with similarities to the controls and
any OTUs associated with them were removed from the dataset before further
characterization of the microbiota. In addition, the contamination predictor tool,
“SourceTracker”, showed that even before implementation of the above, 90% of the
microbial reads were derived from the human specimens and not from the environment.
Even with these quality control measures in place, some people will still be wary of
sequencing results. However, the ability to culture live bacteria from tissue (and not from
any of our environmental controls) further suggests that organisms are present within the
breast. These results are consistent with a study published in 1988 from the University of
Michigan in which bilateral breast tissue from 30 women undergoing either breast
reductions or enhancements were analyzed by culture (Thornton et al., 1988). The most
abundant

organisms

identified

were

coagulase-negative

staphylococci,
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Propionibacterium acnes, Corynebacterium and Lactobacillus. To a lesser extent,
Bacillus, alpha- and beta-streptococci, Clostridium, Peptococcus, Micrococcus,
Enterococcus and gram-negative rods were also cultured. After a 12-month follow-up,
only 2 of the 30 women developed infections, suggesting to the authors that the bacteria
that had been isolated were not contaminants from surgical equipment. All of the
organisms detected by Thornton and colleagues were also identified in our studies by
either culture or HTS. In short, it may be difficult to overcome skepticism. In dealing
with a non-sterile environment of a surgical suite and human body, it may never be
possible to prove conclusively that an isolate was not from the air or other sources. The
low numbers of bacteria compared to other body sites also make it hard to prepare
histological sections that show the organisms within tissues.

7.1.1

Why do these bacteria not induce infections or
inflammation

Similar to the Thornton study, Bacillus and Propionibacterium (acnes and granulosum)
were isolated from our tissue specimens. Whole genome sequencing performed on one
Bacillus cereus tissue isolate revealed the presence of genes that encode for the toxins
hemolysin BL, non-hemolytic enterotoxin and cytotoxin K, which are believed to
contribute to enteritis caused by this species (Fagerlund et al., 2008). P. acnes and P.
granulosum, which are harmless constituents of the skin microbiota, are associated with
catheter and prosthetic joint infections. Propionibacterium avidum, another skin
commensal, has been implicated in breast abscesses after breast reduction mammoplasty
(Kritikos et al., 2015; Levin et al., 2008). Overall, between 75-2000 cfu/ml were cultured
from homogenized tissue (~190-5000 cfu/gram of tissue), and qPCR performed on tissue
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samples collected from the Irish cohort showed an average of 5x105 16S rRNA gene
copies per gram of tissue. In blood, numbers as low as 10 cfu/ml can induce an
inflammatory response with sometimes fatal outcomes (Potgieter et al., 2015). This
therefore begs the question as to why these organisms did not cause infections or induce
pro-inflammatory responses?
One possibility is that these bacteria have adapted to survive in the breast without being
detected and attacked by the immune system. While B. cereus has the genes that encode
for virulent enterotoxins, they may not be expressed within the mammary environment.
While it is hard to ascertain what these factors could be, as many act in concert with each
other, it has been shown that enterotoxin production is regulated by energy availability,
growth rate, cell numbers, aeration and pH (Ceuppens et al., 2011). For example, the
enterotoxin genes are under the control of the quorum sensing regulator, phospholipase C
regulator (PlcR), hence enterotoxins are produced during stationary phase (Ceuppens et
al., 2011). Thus, the density of cells within the breast may be below the threshold needed
to activate PlcR. Furthermore, lactose has been shown to inhibit enterotoxin production,
even in the absence of growth impairment (Rowan and Anderson, 1997).
It is important to note that the bacteria identified in tissue were mostly at the genus, and
in some cases species, level. Bacterial strains vary greatly in their properties even within
a species. A notable example is E.coli: strain Nissle 1917 is considered a probiotic while
O157:H7 is a deadly gastrointestinal pathogen. Thus, the strains in the breast may be less
virulent then other strains of the same species known to cause infections and/or induce
pro-inflammatory responses.
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Another potential reason for the lack of infection and inflammation is the presence of
mechanisms within the mammary gland, similar to those in the GIT, that ensure
homeostasis. Two of them, compartmentalization and immune hyporesponsiveness, are
discussed below.

7.1.1.1

Compartmentalization

It had long been a subject of debate as to why healthy individuals do not mount an overt
pro-inflammatory response against their gut commensals even though they share the
same molecular patterns as pathogens, which do trigger an inflammatory cascade. It was
not until a paper published in 2000 that we began to appreciate the importance of hostmicrobe compartmentalization in maintaining homeostasis (Macpherson et al. 2000). In
this paper, it was shown that specific pathogen free mice lacked serum IgG antibodies
specific against Enterobacter cloacae, the dominant aerobe in the gut of these mice.
Upon systemic intravenous administration of 106 cfu of live bacteria, a strong IgG
response against E. cloacae was mounted. This showed that the non-responsiveness
observed in the serum of un-manipulated mice was due to ignorance rather than
tolerance.
The single layer of epithelial cells lining the lumen of the gut creates a physical barrier
between the luminal contents and the “inside” of the body and plays an essential role in
compartmentalization (Peterson and Artis, 2014). When this barrier is disrupted,
microbial translocation occurs resulting in an inflammatory response (Adams et al., 2008;
Dubinsky et al., 2006; Fava and Danese, 2011; Pastor Rojo et al., 2007). In a similar
fashion, the ducts and the lobules of the mammary glands are made up of a lumen,
surrounded by epithelial cells that form a stratified cuboidal epithelium (Chapter 1).
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While this is different than the simple columnar epithelium of the GIT and has more of a
role in secretion and absorption, it still provides a protective physical barrier against
environmental agents. During lactation, milk and the bacteria present in it, are
sequestered within the lumen of these ducts and lobules, which could explain the lack of
infection and inflammation while the mother is breast-feeding. Even though our tissue
samples were collected from non-gravid/non-lactating women, some of whom never had
children, there is still an extensive ductal system in the “resting” state and in nulliparous
women (Chapter 1). Thus, there is the possibility that the bacteria detected in our tissue
samples (composed of a collection of ducts surrounded by adipose tissue) are
compartmentalized within the lumen of these ducts and are not found within the
surrounding adipose rich stroma. Case reports of breast infections caused by S. aureus
and P. avidum report liponecrosis and adipose edema, with the ability to culture
organisms from these areas (Jari et al.; Kritikos et al., 2015; Levin et al., 2008). These
observations, to some degree, would support the idea that infections occur when bacteria
penetrate into the stroma. To determine whether bacteria were localized within the ducts,
histological sections were stained with methylene blue or probed with an antibody against
peptidoglycan (Appendix 8.3). Unfortunately the methods used did not allow us to
determine where these bacteria localized. Scanning electron microscopy could be
informative, but with so few organisms present, it could take many samples to find the
organisms.

7.1.1.2

Immune hyporesponsiveness

Another mechanism that could help maintain homeostasis, regardless of where the
bacteria are localized, could be an altered state of immune regulation. Immune
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hyporesponsiveness in the GIT is one way in which the host can co-exist with the trillions
of bacteria that reside there (Maynard et al., 2012). For example, intestinal macrophages
are phenotypically and functionally different than those derived from sterile sites, like the
blood. Upon exposure to either Gram negative or Gram positive organisms these
intestinal macrophages produce less inflammatory cytokines compared to blood
monocytes (Smythies et al., 2005). Although there is no data for human breast
macrophages, bovine mammary macrophages are also less responsive against pathogens
than blood monocytes and are also less effective at priming antigen-specific
inflammatory T cells (Politis et al., 1991, 1992), collectively protecting the host against
immune related tissue pathology (Günther et al., 2012).

7.2 Factors contributing to the microbial differences
between breast cancer patients and healthy controls
Bacterial profiles were shown in Chapter 5 to differ between breast tissue from women
who are healthy and normal adjacent tissue from those with breast cancer. We
hypothesized that these differences could be contributing to disease development since
women with cancer had higher relative abundances of bacteria that induce host DNA
damage and lower relative abundances of bacteria that can inhibit tumour growth
(properties that have been shown by others).
There is the possibility, however, that these differences are a consequence rather than a
cause of the disease. It is well established that the tumour mass creates an environment
vastly different than the surrounding tissue. Metabolism differs so much so that metabolic
readouts can be used as biomarkers for tumour detection (Balog et al., 2013; Bathen et
al., 2013; Budczies et al., 2012). However, despite these metabolic differences, which
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could impart a selective advantage for one organism(s) over another, our microbiota
analysis of tumour tissue vs normal adjacent tissue showed no differences in bacterial
profiles. Since normal adjacent tissue is more similar to healthy tissue (i.e. from women
without disease) than to tumour tissue, I am inclined to believe that the differences
observed between healthy and normal adjacent tissue were present before the
development of the tumour. However, this is not to say that host metabolites have no role
in shaping the breast microbiome. Perhaps due to genetics or lifestyle factors (diet, stress,
smoking etc) women who develop breast cancer have different metabolic profiles than
those who do not, which consequently influence the bacterial patterns in the breast. For
example, in our healthy cohort, higher relative abundances of Prevotella were observed,
and this genus has the ability to uptake and metabolize estradiol, which in turn enhances
bacterial growth (Kornman and Loesche, 1982). Studies in pre- and post-menopausal
women have shown that estradiol levels are lower in normal adjacent tissue of breast
cancer patients than tissue from healthy controls (Geisler, 2003; Savolainen-Peltonen et
al., 2014). Perhaps due to these low levels of estrogen in breast cancer patients,
Prevotella strains do not have the optimal energy requirements for growth, which could
explain the lower levels of Prevotella observed in breast cancer patients compared to
healthy controls.
A metabolomics analysis is currently being performed on tissue samples and hopefully
will provide information on how the host can shape this tissue microbiome, and also on
the metabolic activity of the microbes (i.e. bacterial metabolites) and how they interact
with the host (i.e. bacterial induced host metabolites). It may even shed light on how
these breast tissue bacteria might contribute to, or help prevent, breast cancer
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development. Our preliminary analysis does show that there are higher levels of ceramide
in healthy tissue compared to normal adjacent tissue from breast cancer patients.
Ceramide is a pro-apoptotic signaling molecule that controls aberrant cell growth and
there is the possibility that probiotics, like L. rhamnosus GR-1, can breakdown
lactosylceramide (found in high abundances in milk), into ceramide (Appendix 8.4),
possibly protecting against breast cancer development in lactating women. Other strains,
found within tissue, could also have similar properties.
It appears that the breast microbiome can be influenced by bacterial composition at distal
sites. Women with celiac disease, who are known to have altered gut microbial
communities, have different microbial profiles in their milk compared to healthy mothers
(Olivares et al., 2015). Thus, there is the possibility that the differences in bacterial
communities observed between healthy and breast cancer patients could be a reflection of
differences in the GIT. Indeed, the gut microbiota of post-menopausal women with breast
cancer is different than that of disease free subjects (Goedert et al., 2015). A possible way
to test this concept would be to examine the gut microbiota of women prescribed
antibiotics or who have had radical changes in diet and then determine whether these
changes alter the breast microbiota, possibly through collection of nipple aspirate fluid. If
true, this would have important implications, and may provide a means to manipulate the
breast microbiota in order to mitigate disease and promote health.
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7.3 The influence of the breast tissue microbiome on the
response to chemotherapy
7.3.1

The ability of bacteria to bio-transform drugs

In Chapter 5, I present a rationale for how some bacteria could promote breast cancer
development and how others could help prevent it. But the breast microbiota could have a
significant impact on women’s health irrespective of its role in breast cancer
development, by its ability to modulate the efficacy of chemotherapeutics. As shown in
Chapter 2, chemotherapy drastically changed microbial profiles in human milk as early as
Week 2 after the start of treatment. To test the reverse, E.coli, the most relatively
abundant organism within breast tumours, was used as a model to test the impact of
bacteria on cancer treatment. It was found that E. coli had the ability to bio-transform a
variety of drugs used to treat various cancers, leading to decreased efficacy in vitro in
half of the drugs tested (Lehouritis et al., 2015) (Table 7-1). This was further elucidated
in vivo, as gemcitabine was less effective at controlling established tumours that had been
intra-tumourally injected with E.coli compared to PBS. The bio-modulation that occurred
in gemcitabine, after incubation with pure bacterial cultures, is consistent with possible
acetylation. Xenobiotics are metabolized in two distinct phases, the 2nd of which includes
acetylation (Omiecinski et al., 2011). Byproducts of acetylation are typically more
hydrophilic than the parent compound and therefore more readily excreted from the cell
(Omiecinski et al., 2011). Certain strains of E.coli have been shown to possess Nacetyltransferases, the enzymes responsible for acetylation (Chaslus-Dancla et al., 1986;
White-Ziegler et al., 2002). So, a possible mechanism explaining our results could be that
N-acetlytransferases from E.coli, acetylate gemcitabine, which decreases drug efficacy by
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either (i) promoting faster removal of the drug from the tumour once it has entered or (ii)
inhibiting drug uptake, preventing the drug from entering the tumour in the first place.

Table 7-1. Effects of bacteria on chemotherapeutic drug cytotoxicity in vitro
E.coli Nissle 1917, grown to log phase, was incubated for 2 hours with each of the drugs
listed below. After incubation, the drug solution was filter sterilized to remove bacteria
and then added to plates containing the 4T1 mouse mammary carcinoma cell line. Drug
cytotoxicity was measured using the Cell Titre 96 Aqueous One solution Cell
Proliferation Assay (Promega).
Drug
Gemcitabine
Doxorubicin
Daunorubicin
Mitoxantrone
Idarubicin
Capecitabine
5-fluorouracil
Vinblastine
Irinotecan
Estramustine
fludarabine
Tegafur

7.3.2

Efficacy
decreased
decreased
decreased
decreased
decreased
no change
no change
no change
no change
no change
increased
increased

The ability of bacteria to modulate the immune system
which indirectly effects drug therapy

In addition to the direct effects that bacteria can have on drug efficacy, they can also have
indirect effects. Common drugs administered to women to treat breast cancer include
doxorubicin (or epirubicin), paclitaxel, gemcitabine and 5-flurouracil (5-FU). While their
primary mode of action is disruption of DNA synthesis or microtubule formation, their
efficacy may also depend on the engagement of the immune system. For example, 5-FU
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and gemcitabine have been shown to sensitize tumours to CD8+ T cell and NK cell
mediated cytotoxicity and to reduce the levels of myeloid derived suppressor cells,
thereby restoring CD8+ T cell and NK cell functionality (Ghiringhelli and Apetoh, 2015;
Weir et al., 2011). Both paclitaxel and doxorubicin upregulate the cation-independent
mannose-6-phosphate receptor on the surface of tumor cells, thereby increasing the
efficiency of granzyme B mediated killing by cytotoxic T lymphocytes (CTL) and NK
cells (Ramakrishnan et al., 2010). Doxorubicin has also been shown to mediate tumour
infiltration of a subset of dendritic cells that are highly efficient at presenting tumour
antigens to CTLs (Ma et al., 2013). This interaction between the immune system and
chemotherapeutics for optimal tumour killing is further highlighted by the fact that (i)
synergy has been observed in mouse models of solid tumours between chemotherapy and
immunotherapy (Nowak et al., 2003); (ii) immune-deficient mice do not respond as well
to certain chemotherapeutics compared to their immune-competent counterparts (Casares
et al., 2005; Tesniere et al., 2010) and (iii) patients with genetic immune defects are less
responsive to chemotherapy (Ghiringhelli et al., 2009; Tesniere et al., 2010). Therefore if
a patient does not have a proper functioning immune system, then the engagement of the
immune system by chemotherapeutics will not be fully exploited. This could partly
explain why drug therapy is so variable between patients even within the same subtype
and stage.
One of the most well studied and established factors that modulate the immune system is
our microbiota (Hooper et al., 2012; Macpherson and Harris, 2004). The importance of
the microbiota in cancer treatment was recently unraveled by two groups who showed
that chemotherapy was not as effective in germ-free and antibiotic treated mice because
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of inefficient priming of immune cells (Iida et al., 2013; Viaud et al., 2013). In the Viaud
study, Lactobacillus johnsonii and Enterococcus hirae could reverse these drug defects,
while E. coli could not. E. coli was the most abundant organism observed in our breast
tumour specimens while Lactobacillus presence was negligible. Thus, antimicrobial or
probiotic therapy to try and alter the breast microbiota might be worth considering in
order to improve drug efficacy. However, what these strategies may entail would have to
be considered in the context of the drug and the immune response elicited as opposite
bacterial effects were observed in the Iida study- Lactobacillus (L. murinum, L.
intestinalis and L. fermentum) presence was negatively correlated with efficacy while
E.coli showed a positive correlation.

7.4 Future directions
A common thread throughout this thesis had been the idea that one’s microbiota can
modulate health and disease. While it is informative to study bacterial composition and
function once disease has developed, there are merits to examining how factors that shape
one’s microbiome during infancy, such as breast feeding, can influence disease risk later
in life.
In the milk study presented in Chapter 3, we showed that bacterial communities are
highly variable amongst healthy women. One mother (Subject 32) had a milk microbiota
composed of 72% Enterobacteriaceae and no Bifidobacterium nor Lactobacillus while in
another mother (Subject 6), who gave birth vaginally and at term like subject 32,
Enterobacteriaceae made up only 0.8% of her microbiota with Bifidobacterium (24.5%)
and Lactobacillus (8%) dominating. The latter are generally associated with health
whereas Enterobacteriaceae are more associated with disease at various body sites. An
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important question that therefore arises from these results is whether there is a milk
microbiota that is “healthier” than another or whether each unique microbiota is adapted
for a particular host and is the best profile for that individual and her offspring.
To help address this idea, we had intended on administering human milk from subject 6
(high Bifidobacterium/Lactobacillus, low Enterobacteriaceae) to neonatal germ free
mice

and

compare

the
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outcome
high

with

milk

from

Enterobacteriaceae)

in

Subject
terms

32
of

(low

immune

development and function over time. A collaboration was established with Dr. Sven
Petterrson of the Karolinska Institute and the studies were planned for his research site in
Singapore. However, too few animals were available to provide us with enough
meaningful data, so we did not go ahead with the study. Nevertheless, this remains a
worthwhile experiment and if differences were to exist, animal models of breast cancer
could help elucidate whether the different immune effects induced by different milk
microbial communities would put the offspring at a higher risk of breast cancer
development.

7.5 Concluding remarks
The studies conducted on the breast tissue and the breast milk microbiotas presented in
this thesis raise important questions as to what bacterial profiles are considered “healthy”
and what factors influence their composition. Longitudinal studies following lactating
women over a span of a few months or even years would give us a better appreciation of
the factors that shape the milk microbiota (i.e. diet, antibiotics, stress, probiotic intake)
and how quickly the microbiota can rebound from these changes. If further studies show
that milk and tissue microbial communities are similar, human milk could provide a non-
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invasive way in which to study factors that shape the tissue microbiota. Future studies
that monitor healthy subjects (from either those from whom we collect milk or tissue) for
breast cancer development could provide more insight into the organisms that may drive
disease progression. Once diagnosed with cancer, antimicrobial or probiotic therapy
might be worth considering to try and alter the breast microbiota in order to improve the
efficacy of chemotherapy. Overall, the results presented in this thesis represent a new line
of thought that had not been considered before. Hopefully, the data will stimulate new
areas of research that helps prevent breast cancer development or improves treatment
strategies.
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8

Appendix

8.1 Optimization of DNA extraction methods for breast milk
and breast tissue
8.1.1

Breast milk

Two different DNA extraction protocols were compared to determine which one would
generate higher yields of bacterial DNA. The methods followed were by Hunt;
“Characterization of the diversity and temporal stability of bacterial communities in
human milk” (Hunt et al., 2011) and Martin; “Cultivation-independent assessment of the
bacterial diversity of breast milk among healthy women” (Martín et al., 2007). A
schematic of each method is presented in Figure 8-1. Some modifications to the above
protocols were also compared. For Hunt’s protocol, 1ml and 2ml of milk were also tested
as well as 0.5ml, 1ml and 2ml of milk that had been centrifuged at 20,000 x g for 10min
(as per the Martin protocol). For the Martin protocol, DNA was also extracted from 2ml
of milk pellet.
Three different breast milk samples were tested with the above methods. After extraction,
the DNA was amplified using HDA primers, which amplify the V2-V3 hypervariable
region of the 16S rRNA gene (Table 8-1). The PCR was carried out in a 50µl reaction
containing 10µl of DNA template (or nuclease free water as a negative control), 2.5mM
MgCl2, 0.64mM of each primer, 5µl of 10X PCR Buffer (Invitrogen), 0.21mM dNTPs,
0.05U Taq Polymerase (Invitrogen) and 0.15µg/µl of bovine serum albumin. Thermal
cycling was carried out in an Eppendorf Mastercyler using a step-down approach with an
initial denaturation of 94oC for 2min followed by 9 cycles of 94oC for 45s, 61oC for 45s,
72oC for 45s and then another 14 cycles of 94oC for 45s, 61oC for 45s,72oC for 45s. This
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was followed by an elongation step at 72oC for 2 min. After PCR, samples were run on a
1.5% TAE agarose gel for 1hr at 120V, stained with 0.5µg/ml ethidium bromide for
20min and then viewed under UV light in an AlphaImager (Alpha Innotech Corporation).

8.1.2

Breast tissue

65µl, 100µl, 200µl and 400µl of homogenized tissue [0.4g/ml], representing 26mg,
40mg, 80mg and 160mg respectively were used for extractions following the protocols
outlined by Hunt and Martin (Figure 8-1), with the exception of Martin’s initial
centrifugation step. These weights were chosen based on the recommendations outlined
in the QIAamp DNA Mini Kit (max 25mg for tissue) and the QIAamp DNA stool Mini
Kit (180-220mg of stool). In addition to the above protocols, a method used to detect
bacteria in colonic mucosa of patients with IBD was also tested (Sproule-Willoughby et
al., 2010) (Figure 8-2). Three different tissue samples were extracted with these 3
methods and amplified as per the milk samples.
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Hunt protocol
Based on QIAamp DNA Mini Kit
0.5ml milk

500µg lysozyme, 50µg
mutanolysin, 4µg lysostaphin
37oC, 1hr
Bead beading:
30s, 4800rpm x3

Martin protocol
Based on QIAamp DNA Stool Mini Kit
1ml milk, centrifuged at 20,000 x g
for 10min

1.4ml Buffer ASL
added to pellet

Bead beading:
30s at 4800rpm
95oC, 5min

20µl proteinase K
200µl Buffer AL
56oC, 30min; 95oC, 15min
200µl ethanol
100µl 3M sodium
acetate

Samples added to
Qiagen columns and
washed as per kit
instructions

DNA eluted in 120µl
Buffer AE

15µl proteinase K
200µl Buffer AL
70oC, 10min
200µl ethanol

Samples added to
Qiagen columns and
washed as per kit
instructions

DNA eluted in 120µl
Buffer AE

Figure 8-1. Schematic of DNA extraction protocol for bacterial detection in breast
milk
These published methods were also used for bacterial detection in breast tissue.
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Sproule-Willoughby protocol
Based on QIAamp DNA Mini Kit
80µl tissue

200µl lysozyme
solution1
37oC, 30min
200µl Buffer ATL
20µl proteinase K

Bead beading:
30s, 4800rpm x3
56oC, 30min; 95oC, 10min
200µl Buffer AL
70oC, 10min
200µl ethanol

Samples added to
Qiagen column and
washed as per kit
instructions

DNA eluted in 60µl Buffer AE

Figure 8-2. Schematic of DNA extraction for bacterial detection in breast tissue
This protocol was also compared to the ones presented in Figure 8-1. 1lysozyme
solution= 20mg/ml lysozyme (Sigma) in 20mM Tris-HCl pH 8.0, 2mM EDTA and 1.2%
Triton X-100.
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8.1.3

Chosen method for extractions

Based on band intensities of the amplicons after running the PCR on the gel, the Martin
protocol using 2ml of milk and 400µl of tissue produced the strongest band, indicative of
a higher yield. No bands were detected in the no-template negative control.
Numerous studies comparing various DNA extraction methods have shown that bead
beading gives a better representation of bacterial diversity in mixed samples (Yuan et al.,
2012). Bead beading can, however, shear DNA, causing lower DNA yields after
amplification (Lever et al., 2015). To assess whether the bead beading time could be
increased without losing DNA integrity, 30s of bead beading (Martin protocol) was
compared to 60s, repeated twice. Since longer bead beading did not appear to change
amplicon yields, this adjustment was made to the Martin protocol and used for both milk
and tissue extractions.

8.2 Denaturing gradient gel electrophoresis
DNA extracted from breast tissue was analyzed by DGGE before being sent for HTS, to
get an idea of how diverse the bacterial communities were in the samples. The U968fGC/L1401r primer pair, which amplifies the V6-V8 region of the 16S rRNA gene, was
used (Table 8-1). The PCR was carried out in a 50µl reaction containing 10µl of DNA
template (or nuclease free water as a negative control), 3.0mM MgCl2, 0.2mM of each
primer, 5µl of 10X PCR Buffer (Invitrogen), 0.2mM dNTPs, 0.05U Taq Polymerase
(Invitrogen) and 0.15µg/µl of bovine serum albumin. Thermal cycling was carried out in
an Eppendorf Mastercyler under the following conditions: Initial denaturation at 95oC for
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2min followed by 35 cycles of 95oC for 30s, annealing at 56oC for 40s, elongation at
72oC for 60s and then a final elongation step of 72oC for 5min.
Following amplification the products were then run on a 30-70% denaturing gradient gel.
Preparation of gradients and gel electrophoresis were carried out using the D-code
Universal Detection system (Bio-rad) following the manufacturers protocol. A 30% and
70% denaturing solution were made up using the recipe outlined in Table 8-2. 50 µl of
TEMED [N,N,N′,N′-tetramethylethylenediamine; Sigma] and 90 µl of 10% ammonium
persulphate (Bio-Rad) were added to each solution to promote polymerizatiom. Gels
were allowed to polymerize overnight. Either 20µl (Figure 8-3A) or 75µl (Figure 8-3B)
of PCR product were mixed with 2× loading buffer (0.25ml of bromophenol blue [2%,
Sigma], 0.25ml of xylene cyanol [2%, Sigma], 7ml of glycerol, and 2.5ml of ddH2O) and
loaded into the wells. Gels were run at 130 V in 1× TAE at a constant temperature of
60oC until the second dye front (xylene cyanol) approached the end of the gel. After
electrophoresis, gels were removed, allowed to cool before the removal of the glass-plate
sandwich, stained for 20 min in 5µg/ml ethidium bromide, and destained for 10 min in 1×
TAE. Gels were viewed under UV light in an AlphaImager (Alpha Innotech
Corporation).
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Table 8-1. Primers used in the studies discussed in the appendix
Bolded sequence refers to the GC clamp. The qPCR primers target genes from
L.rhamnosus GR-1. pfk= 6 phosphofruktokinase. 1(Burton and Reid, 2002), 2 (Martín et
al., 2007).
Gene
HDA-1
HDA-2
U968F-GC
L1401r
orf_2365-F
orf_2365-R
orf_1121-F
orf_1121-R
orf_817-F
orf_817-R

Primer sequence
5’ ACTCCTACGGGAGGCAGCAG 3’
5’ GTATTACCGCGGCTGCTGGCA 3’
5’CGCCCGGGGCGCGCCCCGGGCGGGGCA
CGGGGGGAACGCGAAGAACCTTAC 3’
5’CGGTGTGTACAAGACCC 3’
5’ CTTTGGAACATTGCCTTGGA 3’
5’ TCTTGCGTGTAGTTGGTGGA 3’
5’ CTAAATGAACAAGGCAATCCAA 3’
5’ TCCAAGACTGCGAACAAGG 3’
5’ CATTATCCCCGAACACGA 3’
5’ GAAATCACCATAGGCAGCAA 3’

Target
V2-V3 region 16S
rRNA gene1
V6-V8 region 16S
rRNA gene2
(DGGE)
glucosylceramidase
(qPCR)
beta-galactosidase
(qPCR)
pfk (qPCRhousekeeping
gene)

Table 8-2. Recipe for making denaturing polyacrylamide gel solutions
40% acrylamide/bisacrylamide solution (Bio-rad)
50X TAE
Urea
Formamide
ddH2O

30%
5ml

70%
5ml

0.5ml
3.15g
3ml
16.5ml

0.5ml
7.35g
7ml
12.5ml
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Figure 8-3. Denaturing gradient gel electrophoresis analysis on breast tissue
DNA was extracted from normal-adjacent tissue from 9 women with tumours and the
corresponding PBS environmental controls. DNA was also extracted from 9 healthy
tissue samples from women who were disease free. The 16S rRNA gene was amplified
using primers that span the V6-V8 hypervariable regions (U968/L1401). The PCR
products were then run on a 30-70% denaturing gradient gel and stained with ethidium
bromide. (A) DGGE gel with 20µl of PCR product loaded into the wells. “N” = normal
adjacent tissue and “E”= PBS environmental controls. (B) DGGE gel with 75µl of PCR
product loaded into the wells. With the exception of two faint bands in 17E, no bands
were detected in any of the other environmental controls
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8.3 Histology
Histology was performed on the breast tissue samples to determine where bacteria
localize within the mammary glands. Upon collection, a small piece of fresh tissue was
placed in a cryomold filled with OCT (Tissue-Tek), snap frozen in liquid nitrogen and
then stored at -80oC. Frozen tissue samples were cut into 5µm sections using a Leica CM
1850 cryostat set at an internal temperature of -30oC. Sections were captured onto
SuperfrostTM Plus microscope slides (FischerBrand), dried overnight at room temperature
and then stored at -80oC until use.

8.3.1

Simple stain

Frozen slides were taken out of the -80oC freezer, allowed to warm up to room
temperature, and then heat fixed by passing through the flame of a Bunsen burner. Slides
were then covered with 1% methylene blue stain for 1min and excess stain washed off
with ddH2O. Slides were then viewed with a Zeiss AxioSkop microscope using both the
40X and 100X objectives, under oil immersion. As a positive control, an overnight
culture of Lactobacillus rhamnosus GR-1 was thinly spread over the slides before being
heat fixed.
Unless distinct and large numbers of bacteria are present, as with the positive control, a
simple stain is not helpful in detecting bacteria in breast tissue (Figure 8-4). However,
this simple stain did show that we had good quality slides with breast architecture intact.
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A

B

Figure 8-4. Methylene blue stain of breast tissue cryosections
Cryosections of 5µm breast tissue samples were stained with 1% methylene blue solution
for 1 min and viewed under oil immersion at 400X magnification. (A) Image of normal
adjacent breast tissue from a woman with stage 1 invasive breast cancer. Image is
representative of 3 different clinical samples. (B) Image of tissue section with an
overnight culture of Lactobacillus rhamnosus GR-1 spread across the top, to act as a
positive control.
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8.3.2

Immunohistochemistry

We next tried to detect bacteria using an antibody specific for peptidoglycan, a molecule
present in all bacterial cell walls. This antibody was used by a group at McMaster
University to detect bacteria present in the human brain (Branton et al., 2013). First, in
order to determine the versatility of the antibody in detecting different bacteria,
immunohistochemistry

was

performed

on

pure

cultures

of

Bacillus

cereus,

Staphylococcus epidermidis and L. rhamnosus GR-1.
Overnight cultures of each organism were placed on two microscope slides, left to dry
and then heat fixed. Endogenous peroxidases were inhibited by covering the slide with a
0.3% H2O2 solution for 20min, which was then washed with TBS for 5min. One slide
received acid treatment and the other did not. According to the manufacturer, pretreatment with a strong acid for Gram-positive bacteria (or a detergent, for Gramnegative bacteria), may be needed to expose the epitopes. For those receiving acid,
25mM of HCl was added to the slides for 5min and then washed 3x with TBS. Slides
were then blocked with 5% goat serum for 1 hour. Afterwards, a 1/100 dilution of the
primary antibody (mouse anti-bacterial peptidoglycan monoclonal antibody, EMD
Millipore) was added to the slides and incubated overnight at 4oC. After washing, the
slides were incubated at a 1/500 dilution for 45min with the secondary antibody (HRP
conjugated goat anti-mouse IgG (H+L), Jackson Laboratories). The slides were then
developed in the dark with AEC (3-amino-9-ethylcarbazole) stain (Table 8-3) for 30min
and the reaction stopped with ddH2O. Slides were viewed with a Zeiss AxioSkop
microscope under oil immersion with the 100X objective.
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The antibody only bound to Staphylococcus (Figure 8-5) and neither Lactobacillus nor
Bacillus, regardless of acid treatment. While different acid concentrations could have
been tested, addition of 10mM or 25mM of HCl to the tissue slides ruined the
architecture of the breast. Due to the amount of time and money needed for optimization
and the fact that this was a minor side project, we decided not to pursue this idea further.
Table 8-3. Recipe for AEC stain for immunohistochemistry
AEC stain
16mg AEC powder (Sigma)
4ml DMF
56ml acetate buffer*
40µl 30% H2O2

*Acetate buffer (100ml)
1.36g sodium acetate trihydrate
0.6ml acetic acid
make up to 70ml with ddH2O
adjust pH to 5.2
top up to 100ml

Dissolve DMF and AEC together, then add
acetate buffer, filter into designated bottle,
add in H2O2

20 antibody alone
Mouse anti-bacterial peptidoglycan monoclonal antibody

Figure 8-5. Immuno-staining of breast tissue cryosections.
An overnight culture of Staphylococcus was immunolabeled with anti-peptidoglycan
antibody and developed with AEC. Cultures were treated either with 25mM HCl or
without (image displayed). Positive staining was observed with and without acid
treatment.
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8.4 Examining the ability of the probiotic Lactobacillus
rhamnosus GR-1 to break down lactosylceramide into
ceramide
8.4.1

Background

Lactosylceramide is a lipid molecule ubiquitous on all eukaryotic cells and is a major
component in human and bovine milk (Newburg and Chaturvedi, 1992). Surprisingly,
considering the health benefits of milk, lactosylceramide has properties that could
promote cancer development, such as the ability to stimulate reactive oxygen species
from various types of cells (Arai et al., 1998), the ability to promote VEGF (vascular
endothelial growth factor) induced angiogenesis (Kolmakova et al., 2009) and the ability
to upregulate the expression of PECAM-1 (platelet/endothelial cell adhesion molecule)
(Gong et al., 2004), which is associated with a poor prognosis in breast cancer patients
(Martin et al., 2005). Lactosylceramide, however, can be broken down into ceramide, a
pro-apoptotic signaling molecule that suppresses tumour growth (Obeid et al., 1993;
Ogretmen and Hannun, 2004). Increased ceramide levels also make multi drug resistant
tumours sensitive to therapy (Liu et al., 2004, 2001). Certain strains of probiotic bacteria
have been shown to possess the ability to increase endogenous ceramide levels on tumour
cells, leading to cellular death (Angulo et al., 2011; Di Marzio et al., 2001).
Lactosylceramide is first broken down into glucosylceramide by beta-galactosidase (EC
3.2.1.23), with this intermediate then broken down to ceramide by glucosylceramidase
(EC 3.2.1.45). An RNA-seq experiment performed by a former graduate student in the
lab, examining the effects of different growth conditions on Lactobacillus rhamnosus
GR-1, revealed higher abundance of mRNA transcripts for glucosylceramidase when
GR-1 was grown to stationary phase in milk compared to broth.
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Considering the importance of ceramide in breast cancer risk reduction, I wanted to
explore whether GR-1 did have the ability to break down lactosylceramide to ceramide
and whether the ceramide generated could inhibit breast cancer cell proliferation in vitro.
First, a quantitative real-time PCR (qPCR) experiment was performed to confirm the
RNA-seq results and to determine at what growth phase these enzymes were most active.
The methods for RNA extraction, primer design and qPCR are outlined below.

8.4.2

RNA isolation from bacterial cultures grown in milk or
broth

A fresh overnight culture of L.rhamnosus GR-1 was prepared in 12ml de Man-RogosaSharpe (MRS) media (Difico Laboratories). The culture was diluted in a 96-well plate
and scanned using a Multiskan Ascent (Thermo Scientific) to select a dilution with an
absorbance of approximately 1.09 at 600nm. A culture of this dilution was made from the
fresh overnight culture in sterile PBS. Next 3.3ml of the diluted culture was transferred
into 2 sterile culture tubes and centrifuged for 4 minutes at 12000

x

g. The supernatant

was discarded, the pellet washed twice with sterile PBS, and then re-pelleted for 4
minutes at 12000 x g. Following the washes, the pellet from one tube was resuspended in
3.3ml skim milk that had been pre-warmed to 37oC and the other in 3.3ml MRS. Milk
was prepared by suspending skim milk powder (Sigma) in deionized water to a
concentration of 10% w/v followed by a 5 minute autoclave cycle at 121oC. Next, 2.5ml
of the milk or MRS suspension was added to 47.5ml pre-warmed skim milk or 47.5ml
MRS respectively in a 50ml conical tube, mixed and loosely capped. Immediately, the
culture was placed in the interchange of an anaerobic chamber and following deoxygenation, placed into the chamber’s incubator at 37oC. Milk cultures were grown for
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10 or 22 hours, corresponding to mid-log and stationary phases of growth respectively.
MRS cultures were grown for either 5 or 14 hours, corresponding to mid-log and
stationary phases of growth respectively.

8.4.2.1

RNA stabilization

Upon completion of the incubation period, 20ml of milk or MRS culture was
immediately added to 40ml of Bacterial RNAprotect (Qiagen) containing 50mg/ml
Rifampicin (Sigma) inside the anaerobic chamber. This mixture was thoroughly vortexed
and incubated at room temperature for 10min to allow for full RNA stabilization and then
removed from the chamber. Next, the cultures were centrifuged at 6000

x

g at 4oC for

20min. The supernatant was then discarded and the pellet immediately frozen in liquid
nitrogen and stored at -80oC until extraction.

8.4.2.2

Optimized L.rhamnosus GR-1 RNA extraction

The frozen pellet was immediately suspended and vortexed in 20ml of lysis solution
made from 20ml DEPC treated water; 20mg/ml lysozyme (Sigma), 50U/ml mutanolysin
(Sigma) and 100 µg/ml rifampicin (Sigma). The lysis mixture was then incubated at 37oC
for 45min with vortexing every 5min. After the incubation period, the mixture was
centrifuged at 6000

x

g for 20min at 4oC. The supernatant was discarded and the pellet

suspended in 20ml TRIzol reagent (Invitrogen) and vortexed for 2min. The sample was
then passed through an RNase-free 21 gauge needle and syringe to aid in homogenization
of the pellet followed by incubation at room temperature for 10min. It was then
centrifuged at 12000

x

g for 10min to remove excess contaminant proteins and the

supernatant then transferred to a fresh tube. Next, 4ml chloroform was added and the
sample mixed for 15s by vortexing, incubated at room temperature for 5min and then
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centrifuged at 12000

x

g for 20min. Next 10ml of the upper aqueous phase was

transferred into 500µl aliquots into fresh RNase-free microcentrifuge tubes. RNA was
precipitated with the addition of 5µg nuclease-free glycogen (Ambion), 50µl 3M sodium
acetate and 550µl isopropanol, inverted 40 times and allowed to precipitate at room
temperature for 10min. RNA was then pelleted by centrifugation at 12000 x g for 20min
at 4oC. The resulting pellet was rinsed twice by adding 70% ethanol (non-denatured)
followed by vortexing and centrifugation at 12000 x g for 5min. The pellet was then air
dried for 10min on ice and resuspended in 100µl RNase-free water (Qiagen). Samples
were stored at -80oC until further analysis.

8.4.2.3

Total RNA cleanup and DNA digest

RNA cleanup was carried out using the RNeasy mini-columns (Qiagen) according to the
manufacturer’s instructions. The optimal on-column DNA digest was applied using
RNase-free DNaseI (Qiagen). Clean, DNA-free, total RNA was eluted from the column
with 2 aliquots of 50µl RNase-free water. The RNA was then concentrated via ethanol
precipitation using 5µg glycogen, 2.5 volumes of 100% ethanol and 0.1 volumes of 3M
sodium acetate, incubated overnight at -80oC and centrifuged at 12000

x

g for 30min.

After discarding the supernatant, the pellet was rinsed twice with 75% ethanol, air dried
and then resuspended in 15µl RNase-free water.

8.4.2.4

Analysis of RNA quality

RNA quality was analyzed by loading 1µl total RNA solution on a 1% agarose gel made
with tris-borate (TBE) buffer. Gels were run at 6V/cm for 1 hour, stained with 0.5µg/ml
ethidium bromide in TBE buffer for 20min and then viewed under UV light in an
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AlphaImager (Alpha Innotech Corporation). Quality was determined by the presence of
crisp rRNA bands. High quality samples were then analyzed using a nanodrop (Thermo
Scientific) to ensure a 260nm/280nm ratio between 1.8-2.0 and a 260nm/230nm ratio
above 1.4. Samples meeting these criteria were then used for qPCR.

8.4.3

qPCR primer design

Primers were designed against beta-galactosidase (EC 3.2.1.23), glucosylceramidase (EC
3.2.1.45) and the housekeeping gene 6-phosphofruktokinase (pfk) using the GR-1
genome sequence generated in our lab. Primer3plus (http://biotools.umassmed.edu/cgibin/primer3plus/primer3plus.cgi) was used to design the primers, taking into account the
following considerations:
•

avoid repeats of G or C longer than 3 bases

•

have G and C on the ends of the primers as this helps in specificity

•

length of primer should be between 18-22 nucleotides long

•

avoid nucleotide runs of more than 4bp (so 4 or more of the same nucleotide
beside each other)

•

GC content should be between 50-60%

•

primer annealing temperature should be between 55-60C

•

melting temperature of primers should not differ by more than 2C

•

the amplicon should have a GC content of 40-60%

•

amplicon length for qPCR should be approximately 100bp

Once adequate primers were chosen, the primer sequences were inputted into Beacon
Designer (www.premierbiosoft.com/molecular_beacons/index.html) to verify that the
primer pairs would not form hairpins or cross-dimerize. mfold
(http://unafold.rna.albany.edu/?q=mfold) was used to make sure that the chosen
amplicon would not form secondary structures above the annealing temperature. Finally
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blastn (http://blast.ncbi.nlm.nih.gov) was used to verify the specificity of the primers and
to ensure that it would only bind the gene of interest. The primer sequences used are
summarized in Table 8-1.

8.4.4

Quantitative real time PCR

Synthesis of cDNA from the RNA isolated above was performed using random hexamers
and SuperScript® II Reverse Transcriptase (Invitrogen) according to the manufacturer’s
instructions. Amplification of cDNA by qPCR was performed using the iQ™ SYBR®
Green Supermix (Bio-Rad) using 10µl iQ SyberGreen, 1µl of forward pimer (10µM), 1µl
of reverse primer (10µM), 1µl of cDNA (or DNA standard) and 7µl of ddH20. Reactions
were run in a Rotor-Gene 6000 thermocycler (Corbett) under the following program: an
initial melting ramp from 72°C to 95°C, followed by 35 cycles of 95°C for 45s, 60°C for
45s, and 72°C for 60s, ending with a hold at 95°C for 5 min. Data was analyzed using the
Rotor-Gene 6000 series software (version 1.7; Corbett). A series of standards was created
to quantify gene concentrations during data analysis. Total DNA was isolated from an
overnight culture of GR-1 using InstaGene matrix (Bio-Rad). PCR was carried out in 50µl reaction mixtures consisting of the following components: 1× PCR buffer (Invitrogen),
2.5mM MgCl2 (Invitrogen), 0.2mM dNTP mix, 0.5µM each primer pair used for qPCR
(Table 8-1), 0.05U Taq polymerase (Invitrogen), 2µl template, and ddH2O to reach 50µl.
Amplification was performed in a Mastercycler (Eppendorf) using the following
program: 95°C for 1 min, followed by 30 cycles of 95°C for 45 s, 60°C for 45 s, and
72°C for 60s with a final elongation step of 72°C for 2 min. Products were viewed via
electrophoresis on a 1% agarose gel using 1× TBE, stained with ethidium bromide, and
viewed under UV light in an AlphaImager (Alpha Innotech Corporation). The
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concentration of DNA in each sample was determined using a nanodrop, and a series of
standards with concentrations ranging from 5,000 pg/µl to 5 × 10−3 pg/µl were made.
These standards were used as templates in the qPCR reactions to construct standard
curves with known concentrations of DNA. Genes of interest were normalized to the
housekeeping gene 6-phosphofructokinase (pfk) (EC 2.7.1.11) before determining the
relative fold change compared to log phase growth in broth.
The qPCR confirmed the results of the RNA-seq experiment in that glucosylceramidase
mRNA transcripts are more abundant at stationary phase when GR-1 is grown in milk
compared to broth. Transcripts were also more abundant at log phase when grown in in
milk compared to broth. Beta-galactosidase mRNA transcripts were also significantly
higher when grown in milk compared to broth at log phase but not so when grown to
stationary phase. These results are displayed in Figure 8-6.
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Figure 8-6. qPCR results showing the relative fold change of the genes involved in
the breakdown of lactosylceramide to ceramide
Concentrations of each gene were determined using a standard curve and then normalized
to the house keeping gene, pfk. Abundances are displayed as fold changes compared to
log phase growth in broth (“log_broth”). Log phase= 5hr broth and 10 hour milk and
stationary phase=14 hour broth and 22hr milk. For all variables with the same letter (“a”,
“b”, “c”, “d”, “e”, “f”, “h”) the difference between the means is statistically significant
following the Bonferroni multiple test correction (p<0.05). Bars represent the mean +/standard deviation of 3 separate experiments.

8.4.5

Verifying the in vitro ability of GR-1 to degrade
lactosylceramide

As qPCR confirmed that the genes involved in lactosylceramide breakdown to ceramide
were upregulated when grown in milk compared to broth, the next step was to show that
GR-1 did have the ability to breakdown lactosylceramide. To test this, GR-1 was grown
to log and stationary phase of growth in nutrient broth supplemented with 17µM of
purified lactosylceramide (Matreya LLC), the concentration present in bovine milk
(Newburg and Chaturvedi, 1992).
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To test the amount of lactosylceramide remaining over time, an ELISA was performed
using an antibody specific against lactosylceramide. While HPLC is the common method
to detect sphingolipids, I opted to try an ELISA. Unfortunately, the antibody purchased
did not recognize sphingolipids and this method had to be abandoned. In the future,
HPLC or LC-MS could be used to measure both lactosylceramide breakdown and the
production of ceramide by GR-1. Bacterial supernatants containing ceramide could then
be used in in vitro experiments to test the ability of the ceramide generated to inhibit
breast cancer cell proliferation.
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Research Foundation, Santa Monica, USA
“Microbes in the breast-important implications”

Feb 2015

Translational Breast Cancer Research Meeting;
Jan 2014
Research Success and Prospects for the Future
London, Canada
“Microbes and Health: Could bacteria play a role in breast cancer
development or treatment. A translational approach to a growing problem.”
South Western Ontario Lactation Consultants Meeting
London, Canada
“The potential role of bacteria in breast cancer development.”

Sept 2012

Crohn’s and Colitis Foundation of Canada, Education Event
Waterloo, Canada
“The interactions between the intestinal microbiota
and the immune system.”

May 2010

Conferences (*denotes oral presentation)
International Union of Microbiological Societies, Montreal, Canada (July 2014)*
Canadian Society of Microbiology Student Oral Symposium, Montreal, Canada (July
2014)*
Rowett-INRA Conference “Microbiology: from sequence to function”, Aberdeen,
Scotland (June 2014)

211

Infection and Immunity Research Forum, London, Canada (Nov 2013)
New York Academy of Science Conference: “Probiotics, Prebiotics and the Host
Microbiome: The Science of Translation”, New York, USA (June 2013)
Oncology Education and Research Day, London, Canada (June 2013)
London Health Research Day, London, Canada (March 2013)
Infection and Immunity Research Forum, London, Canada (Nov 2012)
21st annual Canadian Society for Immunology Conference, Mont Tremblant, Quebec
(April 2008)
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